[{"title": "chronic lymphocytic leukemia", "text": "Combination chemotherapy regimens are effective in both newly diagnosed and relapsed CLL. Combinations of fludarabine with alkylating agents (cyclophosphamide) produce higher response rates and longer progression-free survival than single agents:  Although the purine analogue fludarabine was shown to give superior response rates to chlorambucil as primary therapy,[68][69] no evidence shows early use of fludarabine improves overall survival, and some clinicians prefer to reserve fludarabine for relapsed disease. Chemoimmunotherapy with FCR has shown to improve response rates, progression-free survival, and overall survival in a large randomized trial in CLL patients selected for good physical fitness.", "is_supporting": true, "idx": 0, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Combination chemotherapy regimens are effective in both newly diagnosed and relapsed CLL. Combinations of fludarabine with alkylating agents (cyclophosphamide) produce higher response rates and longer progression-free survival than single agents:  Although the purine analogue fludarabine was shown to give superior response rates to chlorambucil as primary therapy,[68][69] no evidence shows early use of fludarabine improves overall survival, and some clinicians prefer to reserve fludarabine for relapsed disease. Chemoimmunotherapy with FCR has shown to improve response rates, progression-free survival, and overall survival in a large randomized trial in CLL patients selected for good physical fitness."}, {"title": "chlorambucil", "text": "Chlorambucil produces its anti-cancer effects by interfering with DNA replication and damaging the DNA in a cell. The DNA damage induces cell cycle arrest and cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bcl-2-associated X protein, an apoptosis promoter. [7][8][9]  Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA:[10][11][12]  The precise mechanisms by which chlorambucil acts to kill tumor cells are not yet completely understood.", "is_supporting": true, "idx": 1, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Chlorambucil produces its anti-cancer effects by interfering with DNA replication and damaging the DNA in a cell. The DNA damage induces cell cycle arrest and cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bcl-2-associated X protein, an apoptosis promoter. [7][8][9]  Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA:[10][11][12]  The precise mechanisms by which chlorambucil acts to kill tumor cells are not yet completely understood."}, {"title": "chronic lymphocytic leukemia", "text": "Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [2][8] Early on, there are typically no symptoms. [2] Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur.", "is_supporting": false, "idx": 2, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell). [2][8] Early on, there are typically no symptoms. [2] Later, non-painful lymph node swelling, feeling tired, fever, night sweats, or weight loss for no clear reason may occur."}, {"title": "chlorambucil", "text": "Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. [2] For CLL it is a preferred treatment. [3] It is given by mouth.", "is_supporting": false, "idx": 3, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. [2] For CLL it is a preferred treatment. [3] It is given by mouth."}, {"title": "chronic lymphocytic leukemia", "text": "Targeted therapy attacks cancer cells at a specific target, with the aim of not harming normal cells. Targeted drugs used in CLL include venetoclax (a Bcl-2 inhibitor), ibrutinib and  acalabrutinib (Bruton's tyrosine kinase inhibitors), idelalisib and duvelisib (inhibitors of some forms of the enzyme phosphoinositide 3-kinase), as well as monoclonal antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab). [2][71] Notably, some of the effects of the targeted therapies such as BCR inhibitors can be attributed to disrupting the interaction of CLL cells with tumour promoting T cells.", "is_supporting": false, "idx": 4, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Targeted therapy attacks cancer cells at a specific target, with the aim of not harming normal cells. Targeted drugs used in CLL include venetoclax (a Bcl-2 inhibitor), ibrutinib and  acalabrutinib (Bruton's tyrosine kinase inhibitors), idelalisib and duvelisib (inhibitors of some forms of the enzyme phosphoinositide 3-kinase), as well as monoclonal antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab). [2][71] Notably, some of the effects of the targeted therapies such as BCR inhibitors can be attributed to disrupting the interaction of CLL cells with tumour promoting T cells."}, {"title": "obinutuzumab", "text": "Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. [5][6] It was originated by GlycArt Biotechnology AG and developed by Roche. [citation needed]", "is_supporting": false, "idx": 5, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Obinutuzumab, sold under the brand name Gazyva among others, is a humanized anti-CD20 monoclonal antibody used as a treatment for cancer. [5][6] It was originated by GlycArt Biotechnology AG and developed by Roche. [citation needed]"}, {"title": "alemtuzumab", "text": "Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein.", "is_supporting": false, "idx": 6, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Alemtuzumab, sold under the brand names Campath and Lemtrada among others, is a medication used to treat chronic lymphocytic leukemia and multiple sclerosis. [8] In chronic lymphocytic leukemia, it has been used as both a first line and second line treatment. [8] It is given by injection into a vein."}, {"title": "rituximab", "text": "Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [14] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein-Barr virus-positive mucocutaneous ulcers. [14][15][16][17] It is given by slow intravenous infusion (injected slowly through an IV line).", "is_supporting": false, "idx": 7, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [14] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein-Barr virus-positive mucocutaneous ulcers. [14][15][16][17] It is given by slow intravenous infusion (injected slowly through an IV line)."}, {"title": "ibrutinib", "text": "Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia.", "is_supporting": false, "idx": 8, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia."}, {"title": "ofatumumab", "text": "Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [12] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. [8][10] Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States.", "is_supporting": false, "idx": 9, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion. [12] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions. [8][10] Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States."}, {"title": "venetoclax", "text": "Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML). [5][6]  The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness. [6]  Venetoclax attaches to a protein called Bcl-2.", "is_supporting": false, "idx": 10, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML). [5][6]  The most common side effects are low levels of neutrophils (a type of white blood cell), diarrhea, nausea, anemia (low red blood cell counts), nose and throat infection and tiredness. [6]  Venetoclax attaches to a protein called Bcl-2."}, {"title": "idelalisib", "text": "Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. [4][3]  The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110d, the delta isoform of the enzyme phosphoinositide 3-kinase. [6][7] It was developed by Gilead Sciences.", "is_supporting": false, "idx": 11, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers. [4][3]  The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110d, the delta isoform of the enzyme phosphoinositide 3-kinase. [6][7] It was developed by Gilead Sciences."}, {"title": "venetoclax", "text": "Common side effects of venetoclax include neutropenia (low white blood cell count), nausea, anemia, diarrhea, upper respiratory tract infection, fatigue, and thrombocytopenia (low platelet count). Major side effects include tumor lysis syndrome and severe neutropenia. Additionally, this drug may cause fertility problems in males.", "is_supporting": false, "idx": 12, "question_id": "case_study_biomed/question_14.json", "paragraph_text": "Common side effects of venetoclax include neutropenia (low white blood cell count), nausea, anemia, diarrhea, upper respiratory tract infection, fatigue, and thrombocytopenia (low platelet count). Major side effects include tumor lysis syndrome and severe neutropenia. Additionally, this drug may cause fertility problems in males."}, {"title": "International Classification of Diseases for Oncology Morphology Codes (ICD-O-3)", "content": "Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL) Chronic lymphocytic leukemia Chronic lymphoid leukemia Chronic lymphatic leukemia M9826/3 Burkitt cell Leukemia (see also M9687/3)", "is_supporting": false, "idx": 13, "question_id": "case_study_biomed/question_14.json", "text": "Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL) Chronic lymphocytic leukemia Chronic lymphoid leukemia Chronic lymphatic leukemia M9826/3 Burkitt cell Leukemia (see also M9687/3)", "paragraph_text": "Chronic lymphocytic leukemia, B-cell type (includes all variants of BCLL) Chronic lymphocytic leukemia Chronic lymphoid leukemia Chronic lymphatic leukemia M9826/3 Burkitt cell Leukemia (see also M9687/3)"}, {"title": "Leukostasis Pathophysiology/mechanism", "content": "Chronic lymphocytic leukemia - Exact percentage of people diagnosed with chronic lymphocytic leukemia is unknown but a significant number also suffer from hyperleukocytosis.", "is_supporting": false, "idx": 14, "question_id": "case_study_biomed/question_14.json", "text": "Chronic lymphocytic leukemia - Exact percentage of people diagnosed with chronic lymphocytic leukemia is unknown but a significant number also suffer from hyperleukocytosis.", "paragraph_text": "Chronic lymphocytic leukemia - Exact percentage of people diagnosed with chronic lymphocytic leukemia is unknown but a significant number also suffer from hyperleukocytosis."}, {"title": "Leukemia cutis", "content": "Leukemia cutis can occur in most forms of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and prolymphocytic leukemia.", "is_supporting": false, "idx": 15, "question_id": "case_study_biomed/question_14.json", "text": "Leukemia cutis can occur in most forms of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and prolymphocytic leukemia.", "paragraph_text": "Leukemia cutis can occur in most forms of leukemia, including chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and prolymphocytic leukemia."}, {"title": "Childhood leukemia Types", "content": "Chronic lymphocytic leukemia (CLL) is another form of chronic leukemia, but is extremely rare in children.", "is_supporting": false, "idx": 16, "question_id": "case_study_biomed/question_14.json", "text": "Chronic lymphocytic leukemia (CLL) is another form of chronic leukemia, but is extremely rare in children.", "paragraph_text": "Chronic lymphocytic leukemia (CLL) is another form of chronic leukemia, but is extremely rare in children."}, {"title": "Chronic lymphocytic leukemia Signs and symptoms", "content": "Gastrointestinal (GI) involvement can rarely occur with chronic lymphocytic leukemia. Some of the reported manifestations include intussusception, small intestinal bacterial contamination, colitis, and others. Usually, GI complications with CLL occur after Richter transformation. Two cases to date have been reported of GI involvement in chronic lymphocytic leukemia without Richter's transformation.", "is_supporting": false, "idx": 17, "question_id": "case_study_biomed/question_14.json", "text": "Gastrointestinal (GI) involvement can rarely occur with chronic lymphocytic leukemia. Some of the reported manifestations include intussusception, small intestinal bacterial contamination, colitis, and others. Usually, GI complications with CLL occur after Richter transformation. Two cases to date have been reported of GI involvement in chronic lymphocytic leukemia without Richter's transformation.", "paragraph_text": "Gastrointestinal (GI) involvement can rarely occur with chronic lymphocytic leukemia. Some of the reported manifestations include intussusception, small intestinal bacterial contamination, colitis, and others. Usually, GI complications with CLL occur after Richter transformation. Two cases to date have been reported of GI involvement in chronic lymphocytic leukemia without Richter's transformation."}, {"title": "Large granular lymphocytic leukemia", "content": "Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood.", "is_supporting": false, "idx": 18, "question_id": "case_study_biomed/question_14.json", "text": "Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood.", "paragraph_text": "Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder that exhibits an unexplained, chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood."}, {"title": "Chronic leukemia", "content": "Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is categorized as myelogenous or lymphocytic.", "is_supporting": false, "idx": 19, "question_id": "case_study_biomed/question_14.json", "text": "Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is categorized as myelogenous or lymphocytic.", "paragraph_text": "Chronic leukemia is an increase of abnormal white blood cells. It differs from acute leukemia, and is categorized as myelogenous or lymphocytic."}, {"title": "Lymphoid leukemia Classification", "content": "B-cell leukemia T-cell leukemia NK-cell leukemia The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia.", "is_supporting": false, "idx": 20, "question_id": "case_study_biomed/question_14.json", "text": "B-cell leukemia T-cell leukemia NK-cell leukemia The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia.", "paragraph_text": "B-cell leukemia T-cell leukemia NK-cell leukemia The most common type of lymphoid leukemia is B-cell chronic lymphocytic leukemia."}, {"title": "Myeloproliferative neoplasm Causes", "content": "Chronic myelogenous leukemia (BCR-ABL1\u2013positive) Chronic neutrophilic leukemia Polycythemia vera Primary myelofibrosis Essential thrombocythemia Chronic eosinophilic leukemia (not otherwise specified) Mastocytosis All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma).", "is_supporting": false, "idx": 21, "question_id": "case_study_biomed/question_14.json", "text": "Chronic myelogenous leukemia (BCR-ABL1-positive) Chronic neutrophilic leukemia Polycythemia vera Primary myelofibrosis Essential thrombocythemia Chronic eosinophilic leukemia (not otherwise specified) Mastocytosis All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma).", "paragraph_text": "Chronic myelogenous leukemia (BCR-ABL1-positive) Chronic neutrophilic leukemia Polycythemia vera Primary myelofibrosis Essential thrombocythemia Chronic eosinophilic leukemia (not otherwise specified) Mastocytosis All MPNs arise from precursors of the myeloid lineages in the bone marrow. The lymphoid lineage may produce similar diseases, the lymphoproliferative disorders (acute lymphoblastic leukemia, lymphomas, chronic lymphocytic leukemia and multiple myeloma)."}, {"title": "Fludarabine", "content": "Fludarabine, sold under the brand name Fludara among others, is a chemotherapy medication used in the treatment of leukemia and lymphoma. These include chronic lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and acute lymphocytic leukemia. It is given by injection into a vein or by mouth.", "is_supporting": false, "idx": 22, "question_id": "case_study_biomed/question_14.json", "text": "Fludarabine, sold under the brand name Fludara among others, is a chemotherapy medication used in the treatment of leukemia and lymphoma. These include chronic lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and acute lymphocytic leukemia. It is given by injection into a vein or by mouth.", "paragraph_text": "Fludarabine, sold under the brand name Fludara among others, is a chemotherapy medication used in the treatment of leukemia and lymphoma. These include chronic lymphocytic leukemia, non-Hodgkin's lymphoma, acute myeloid leukemia, and acute lymphocytic leukemia. It is given by injection into a vein or by mouth."}, {"title": "Chronic lymphocytic leukemia Treatment", "content": "Alkylating agents approved for CLL include bendamustine and cyclophosphamide.", "is_supporting": false, "idx": 23, "question_id": "case_study_biomed/question_14.json", "text": "Alkylating agents approved for CLL include bendamustine and cyclophosphamide.", "paragraph_text": "Alkylating agents approved for CLL include bendamustine and cyclophosphamide."}, {"title": "HLA-C Disease associations", "content": "Cw1: multinodular goiters C*16: B chronic lymphocytic leukemia", "is_supporting": false, "idx": 24, "question_id": "case_study_biomed/question_14.json", "text": "Cw1: multinodular goiters C*16: B chronic lymphocytic leukemia", "paragraph_text": "Cw1: multinodular goiters C*16: B chronic lymphocytic leukemia"}, {"title": "Ublituximab", "content": "It is also in Phase 2 clinical trials for chronic lymphocytic leukemia.", "is_supporting": false, "idx": 25, "question_id": "case_study_biomed/question_14.json", "text": "It is also in Phase 2 clinical trials for chronic lymphocytic leukemia.", "paragraph_text": "It is also in Phase 2 clinical trials for chronic lymphocytic leukemia."}, {"title": "T-cell prolymphocytic leukemia", "content": "T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement. T-PLL is a very rare leukemia, primarily affecting adults over the age of 30. It represents 2% of all small lymphocytic leukemias in adults. Other names include T-cell chronic lymphocytic leukemia, \"knobby\" type of T-cell leukemia, and T-prolymphocytic leukemia/T-cell lymphocytic leukemia.", "is_supporting": false, "idx": 26, "question_id": "case_study_biomed/question_14.json", "text": "T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement. T-PLL is a very rare leukemia, primarily affecting adults over the age of 30. It represents 2% of all small lymphocytic leukemias in adults. Other names include T-cell chronic lymphocytic leukemia, \"knobby\" type of T-cell leukemia, and T-prolymphocytic leukemia/T-cell lymphocytic leukemia.", "paragraph_text": "T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and predilection for blood, bone marrow, lymph nodes, liver, spleen, and skin involvement. T-PLL is a very rare leukemia, primarily affecting adults over the age of 30. It represents 2% of all small lymphocytic leukemias in adults. Other names include T-cell chronic lymphocytic leukemia, \"knobby\" type of T-cell leukemia, and T-prolymphocytic leukemia/T-cell lymphocytic leukemia."}, {"title": "International Classification of Diseases for Oncology Morphology Codes (ICD-O-3)", "content": "Acute myelogenous leukemia Acute non-lymphocytic leukemia Acute granulocytic leukemia Acute myelogenous leukemia Acute myelocytic leukemia M9863/3 Chronic myeloid leukemia, NOS", "is_supporting": false, "idx": 27, "question_id": "case_study_biomed/question_14.json", "text": "Acute myelogenous leukemia Acute non-lymphocytic leukemia Acute granulocytic leukemia Acute myelogenous leukemia Acute myelocytic leukemia M9863/3 Chronic myeloid leukemia, NOS", "paragraph_text": "Acute myelogenous leukemia Acute non-lymphocytic leukemia Acute granulocytic leukemia Acute myelogenous leukemia Acute myelocytic leukemia M9863/3 Chronic myeloid leukemia, NOS"}, {"title": "Large granular lymphocytic leukemia Epidemiology", "content": "T-LGLL is a rare form of leukemia, comprising 2-3% of all cases of chronic lymphoproliferative disorders.", "is_supporting": false, "idx": 28, "question_id": "case_study_biomed/question_14.json", "text": "T-LGLL is a rare form of leukemia, comprising 2-3% of all cases of chronic lymphoproliferative disorders.", "paragraph_text": "T-LGLL is a rare form of leukemia, comprising 2-3% of all cases of chronic lymphoproliferative disorders."}, {"title": "Ibrutinib History", "content": "In May 2016, a new indication for ibrutinib was approved in the United States for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).", "is_supporting": false, "idx": 29, "question_id": "case_study_biomed/question_14.json", "text": "In May 2016, a new indication for ibrutinib was approved in the United States for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).", "paragraph_text": "In May 2016, a new indication for ibrutinib was approved in the United States for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)."}, {"title": "Pentostatin Uses", "content": "Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.", "is_supporting": false, "idx": 30, "question_id": "case_study_biomed/question_14.json", "text": "Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed.", "paragraph_text": "Pentostatin is also used in chronic lymphocytic leukemia (CLL) patients who have relapsed."}, {"title": "MicroRNA History", "content": "The first human disease associated with deregulation of miRNAs was chronic lymphocytic leukemia.", "is_supporting": false, "idx": 31, "question_id": "case_study_biomed/question_14.json", "text": "The first human disease associated with deregulation of miRNAs was chronic lymphocytic leukemia.", "paragraph_text": "The first human disease associated with deregulation of miRNAs was chronic lymphocytic leukemia."}, {"title": "Mir-223 Involvement in disease", "content": "MicroRNA-223 is commonly repressed in hepatocellular carcinoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, gastric MALT lymphoma, and recurrent ovarian cancer.", "is_supporting": false, "idx": 32, "question_id": "case_study_biomed/question_14.json", "text": "MicroRNA-223 is commonly repressed in hepatocellular carcinoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, gastric MALT lymphoma, and recurrent ovarian cancer.", "paragraph_text": "MicroRNA-223 is commonly repressed in hepatocellular carcinoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, gastric MALT lymphoma, and recurrent ovarian cancer."}, {"title": "Chronic lymphocytic leukemia Diagnosis", "content": "CLL should not be confused with acute lymphoblastic leukemia, a highly aggressive leukemia most commonly diagnosed in children, and highly treatable in the pediatric setting.", "is_supporting": false, "idx": 33, "question_id": "case_study_biomed/question_14.json", "text": "CLL should not be confused with acute lymphoblastic leukemia, a highly aggressive leukemia most commonly diagnosed in children, and highly treatable in the pediatric setting.", "paragraph_text": "CLL should not be confused with acute lymphoblastic leukemia, a highly aggressive leukemia most commonly diagnosed in children, and highly treatable in the pediatric setting."}, {"title": "Venetoclax", "content": "Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).", "is_supporting": false, "idx": 34, "question_id": "case_study_biomed/question_14.json", "text": "Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).", "paragraph_text": "Venetoclax, sold under the brand names Venclexta and Venclyxto, is a medication used to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)."}, {"title": "Chronic lymphocytic leukemia Signs and symptoms", "content": "Complications include a low level of antibodies in the bloodstream (hypogammaglobulinemia) leading to recurrent infection, warm autoimmune hemolytic anemia in 10\u201315% of patients, and bone marrow failure. Chronic lymphocytic leukemia may also transform into Richter's syndrome, the development of fast-growing diffuse large B cell lymphoma, prolymphocytic leukemia, Hodgkin's lymphoma, or acute leukemia in some patients. Its incidence is estimated to be around 5% in patients with CLL.", "is_supporting": false, "idx": 35, "question_id": "case_study_biomed/question_14.json", "text": "Complications include a low level of antibodies in the bloodstream (hypogammaglobulinemia) leading to recurrent infection, warm autoimmune hemolytic anemia in 10-15% of patients, and bone marrow failure. Chronic lymphocytic leukemia may also transform into Richter's syndrome, the development of fast-growing diffuse large B cell lymphoma, prolymphocytic leukemia, Hodgkin's lymphoma, or acute leukemia in some patients. Its incidence is estimated to be around 5% in patients with CLL.", "paragraph_text": "Complications include a low level of antibodies in the bloodstream (hypogammaglobulinemia) leading to recurrent infection, warm autoimmune hemolytic anemia in 10-15% of patients, and bone marrow failure. Chronic lymphocytic leukemia may also transform into Richter's syndrome, the development of fast-growing diffuse large B cell lymphoma, prolymphocytic leukemia, Hodgkin's lymphoma, or acute leukemia in some patients. Its incidence is estimated to be around 5% in patients with CLL."}, {"title": "Waldenstr\u00f6m's macroglobulinemia Diagnosis", "content": "1. IgM monoclonal gammopathy that excludes chronic lymphocytic leukemia and Mantle cell lymphoma", "is_supporting": false, "idx": 36, "question_id": "case_study_biomed/question_14.json", "text": "1. IgM monoclonal gammopathy that excludes chronic lymphocytic leukemia and Mantle cell lymphoma", "paragraph_text": "1. IgM monoclonal gammopathy that excludes chronic lymphocytic leukemia and Mantle cell lymphoma"}, {"title": "Ofatumumab Medical uses", "content": "Its only indication that has received regulatory approval is chronic lymphocytic leukemia (CLL).", "is_supporting": false, "idx": 37, "question_id": "case_study_biomed/question_14.json", "text": "Its only indication that has received regulatory approval is chronic lymphocytic leukemia (CLL).", "paragraph_text": "Its only indication that has received regulatory approval is chronic lymphocytic leukemia (CLL)."}, {"title": "Prolymphocytic leukemia", "content": "Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell prolymphocytic leukemia and T-cell prolymphocytic leukemia. It is usually classified as a kind of chronic lymphocytic leukemia.", "is_supporting": false, "idx": 38, "question_id": "case_study_biomed/question_14.json", "text": "Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell prolymphocytic leukemia and T-cell prolymphocytic leukemia. It is usually classified as a kind of chronic lymphocytic leukemia.", "paragraph_text": "Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell prolymphocytic leukemia and T-cell prolymphocytic leukemia. It is usually classified as a kind of chronic lymphocytic leukemia."}, {"title": "Ibrutinib History", "content": "In January 2019, ibrutinib in combination with obinutuzumab was approved for the treatment of adults with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).", "is_supporting": false, "idx": 39, "question_id": "case_study_biomed/question_14.json", "text": "In January 2019, ibrutinib in combination with obinutuzumab was approved for the treatment of adults with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).", "paragraph_text": "In January 2019, ibrutinib in combination with obinutuzumab was approved for the treatment of adults with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)."}, {"title": "Index of oncology articles C", "content": "\u2013 CEP-2563 dihydrochloride \u2013 CEP-701 \u2013 cephalosporin \u2013 ceramide \u2013 cerebellar hemangioblastoma \u2013 cerebellopontine \u2013 cerebral hemisphere \u2013 cerebrospinal fluid \u2013 cerebrospinal fluid diversion \u2013 cervical \u2013 cervical intraepithelial neoplasia \u2013 cervix \u2013 cetuximab \u2013 cevimeline \u2013 CGP 48664 \u2013 Chamberlain procedure \u2013 chemoembolization \u2013 chemoimmunotherapy \u2013 chemoprevention \u2013 chemoprevention studies \u2013 chemoprotective \u2013 chemoradiation \u2013 chemoradiotherapy \u2013 chemosensitivity \u2013 chemosensitivity assay \u2013 chemosensitizer \u2013 chemotherapeutic agent \u2013 chemotherapy \u2013 chemotherapy-induced peripheral neuropathy \u2013 chest x-ray \u2013 chiasma \u2013 child-life worker \u2013 chitin \u2013 chlorambucil \u2013 chlorine \u2013 chloroma \u2013 chloroquinoxaline sulfonamide \u2013 cholangiocarcinoma \u2013 cholangiosarcoma \u2013 cholelith \u2013 cholestasis \u2013 chondrocyte \u2013 chondroitin sulfate \u2013 chondrosarcoma \u2013 chordoma \u2013 chorioallantoic membrane \u2013 choriocarcinoma \u2013 choroid plexus tumor \u2013 CHPP \u2013 chronic granulocytic leukemia \u2013 chronic idiopathic myelofibrosis \u2013 chronic leukemia \u2013 chronic lymphoblastic leukemia \u2013 chronic lymphocytic leukemia \u2013 chronic myelogenous leukemia \u2013 chronic myeloid leukemia \u2013 chronic myelomonocytic leukemia \u2013 chronic phase \u2013 chronic phase chronic myelogenous leukemia", "is_supporting": false, "idx": 40, "question_id": "case_study_biomed/question_14.json", "text": "- CEP-2563 dihydrochloride - CEP-701 - cephalosporin - ceramide - cerebellar hemangioblastoma - cerebellopontine - cerebral hemisphere - cerebrospinal fluid - cerebrospinal fluid diversion - cervical - cervical intraepithelial neoplasia - cervix - cetuximab - cevimeline - CGP 48664 - Chamberlain procedure - chemoembolization - chemoimmunotherapy - chemoprevention - chemoprevention studies - chemoprotective - chemoradiation - chemoradiotherapy - chemosensitivity - chemosensitivity assay - chemosensitizer - chemotherapeutic agent - chemotherapy - chemotherapy-induced peripheral neuropathy - chest x-ray - chiasma - child-life worker - chitin - chlorambucil - chlorine - chloroma - chloroquinoxaline sulfonamide - cholangiocarcinoma - cholangiosarcoma - cholelith - cholestasis - chondrocyte - chondroitin sulfate - chondrosarcoma - chordoma - chorioallantoic membrane - choriocarcinoma - choroid plexus tumor - CHPP - chronic granulocytic leukemia - chronic idiopathic myelofibrosis - chronic leukemia - chronic lymphoblastic leukemia - chronic lymphocytic leukemia - chronic myelogenous leukemia - chronic myeloid leukemia - chronic myelomonocytic leukemia - chronic phase - chronic phase chronic myelogenous leukemia", "paragraph_text": "- CEP-2563 dihydrochloride - CEP-701 - cephalosporin - ceramide - cerebellar hemangioblastoma - cerebellopontine - cerebral hemisphere - cerebrospinal fluid - cerebrospinal fluid diversion - cervical - cervical intraepithelial neoplasia - cervix - cetuximab - cevimeline - CGP 48664 - Chamberlain procedure - chemoembolization - chemoimmunotherapy - chemoprevention - chemoprevention studies - chemoprotective - chemoradiation - chemoradiotherapy - chemosensitivity - chemosensitivity assay - chemosensitizer - chemotherapeutic agent - chemotherapy - chemotherapy-induced peripheral neuropathy - chest x-ray - chiasma - child-life worker - chitin - chlorambucil - chlorine - chloroma - chloroquinoxaline sulfonamide - cholangiocarcinoma - cholangiosarcoma - cholelith - cholestasis - chondrocyte - chondroitin sulfate - chondrosarcoma - chordoma - chorioallantoic membrane - choriocarcinoma - choroid plexus tumor - CHPP - chronic granulocytic leukemia - chronic idiopathic myelofibrosis - chronic leukemia - chronic lymphoblastic leukemia - chronic lymphocytic leukemia - chronic myelogenous leukemia - chronic myeloid leukemia - chronic myelomonocytic leukemia - chronic phase - chronic phase chronic myelogenous leukemia"}, {"title": "B symptoms \"B symptoms\" in other diseases", "content": "Also seen in chronic lymphocytic leukemia, Hodgkin\u2019s Lymphoma, Burkitt\u2019s Lymphoma.", "is_supporting": false, "idx": 41, "question_id": "case_study_biomed/question_14.json", "text": "Also seen in chronic lymphocytic leukemia, Hodgkin's Lymphoma, Burkitt's Lymphoma.", "paragraph_text": "Also seen in chronic lymphocytic leukemia, Hodgkin's Lymphoma, Burkitt's Lymphoma."}, {"title": "Paul Booth (labor organizer) Personal life", "content": "He died January 17, 2018, from complications of chronic lymphocytic leukemia.", "is_supporting": false, "idx": 42, "question_id": "case_study_biomed/question_14.json", "text": "He died January 17, 2018, from complications of chronic lymphocytic leukemia.", "paragraph_text": "He died January 17, 2018, from complications of chronic lymphocytic leukemia."}, {"title": "Obinutuzumab History", "content": "In January 2019, the US FDA approved ibrutinib in combination with obinutuzumab for people with chronic lymphocytic leukemia/small lymphocytic lymphoma who have not received prior treatment.", "is_supporting": false, "idx": 43, "question_id": "case_study_biomed/question_14.json", "text": "In January 2019, the US FDA approved ibrutinib in combination with obinutuzumab for people with chronic lymphocytic leukemia/small lymphocytic lymphoma who have not received prior treatment.", "paragraph_text": "In January 2019, the US FDA approved ibrutinib in combination with obinutuzumab for people with chronic lymphocytic leukemia/small lymphocytic lymphoma who have not received prior treatment."}, {"title": "Oncology Treatment", "content": "Hodgkin lymphoma (HL) Chemotherapy with ABVD or BEACOPP regimen and Involved field radiation therapy (IFRT). Non-Hodgkin lymphoma (NHL) Chemo-immunotherapy (R-CHOP) for B cell lymphomas, and chemotherapy (CHOP) for T cell lymphomas. Includes acute and chronic leukemias. Acute leukemias includes acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). Chronic leukemias include chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).", "is_supporting": false, "idx": 44, "question_id": "case_study_biomed/question_14.json", "text": "Hodgkin lymphoma (HL) Chemotherapy with ABVD or BEACOPP regimen and Involved field radiation therapy (IFRT). Non-Hodgkin lymphoma (NHL) Chemo-immunotherapy (R-CHOP) for B cell lymphomas, and chemotherapy (CHOP) for T cell lymphomas. Includes acute and chronic leukemias. Acute leukemias includes acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). Chronic leukemias include chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).", "paragraph_text": "Hodgkin lymphoma (HL) Chemotherapy with ABVD or BEACOPP regimen and Involved field radiation therapy (IFRT). Non-Hodgkin lymphoma (NHL) Chemo-immunotherapy (R-CHOP) for B cell lymphomas, and chemotherapy (CHOP) for T cell lymphomas. Includes acute and chronic leukemias. Acute leukemias includes acute lymphoblastic leukemia (ALL), and acute myeloid leukemia (AML). Chronic leukemias include chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML)."}, {"title": "International Classification of Diseases for Oncology Morphology Codes (ICD-O-3)", "content": "MGUS Monoclonal gammopathy, NOS (M9766/1) Angiocentric immunoproliferative lesion LYmphoid granulomatosis Lymphomatoid granulomatosis M9767/1 Angioimmunoblastic lymphadenopathy M9768/1 T-gamma lymphoproliferative disease M9769/1 Immunoglobulin deposition disease Systemic light chain disease Primary amyloidosis M9800/3 Leukemia, NOS M9801/3 Acute leukemia, NOS Blast cell leukemia Undifferentiated leukemia Stem cell leukemia M9805/3 Acute biphenotypic leukemia Acute leukemia of ambiguous lineage Acute mixed lineage leukemia Acute bilineal leukemia M9820/3 Lymphoid leukemia, NOS Lymphocytic leukemia, NOS Lymphatic leukemia, NOS M9823/3 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (see also M9670/3)", "is_supporting": false, "idx": 45, "question_id": "case_study_biomed/question_14.json", "text": "MGUS Monoclonal gammopathy, NOS (M9766/1) Angiocentric immunoproliferative lesion LYmphoid granulomatosis Lymphomatoid granulomatosis M9767/1 Angioimmunoblastic lymphadenopathy M9768/1 T-gamma lymphoproliferative disease M9769/1 Immunoglobulin deposition disease Systemic light chain disease Primary amyloidosis M9800/3 Leukemia, NOS M9801/3 Acute leukemia, NOS Blast cell leukemia Undifferentiated leukemia Stem cell leukemia M9805/3 Acute biphenotypic leukemia Acute leukemia of ambiguous lineage Acute mixed lineage leukemia Acute bilineal leukemia M9820/3 Lymphoid leukemia, NOS Lymphocytic leukemia, NOS Lymphatic leukemia, NOS M9823/3 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (see also M9670/3)", "paragraph_text": "MGUS Monoclonal gammopathy, NOS (M9766/1) Angiocentric immunoproliferative lesion LYmphoid granulomatosis Lymphomatoid granulomatosis M9767/1 Angioimmunoblastic lymphadenopathy M9768/1 T-gamma lymphoproliferative disease M9769/1 Immunoglobulin deposition disease Systemic light chain disease Primary amyloidosis M9800/3 Leukemia, NOS M9801/3 Acute leukemia, NOS Blast cell leukemia Undifferentiated leukemia Stem cell leukemia M9805/3 Acute biphenotypic leukemia Acute leukemia of ambiguous lineage Acute mixed lineage leukemia Acute bilineal leukemia M9820/3 Lymphoid leukemia, NOS Lymphocytic leukemia, NOS Lymphatic leukemia, NOS M9823/3 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (see also M9670/3)"}, {"title": "Mercaptopurine", "content": "Mercaptopurine (6-MP), sold under the brand name Purinethol among others, is a medication used for cancer and autoimmune diseases. Specifically it is used to treat acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis. For acute lymphocytic leukemia it is generally used with methotrexate. It is taken by mouth.", "is_supporting": false, "idx": 46, "question_id": "case_study_biomed/question_14.json", "text": "Mercaptopurine (6-MP), sold under the brand name Purinethol among others, is a medication used for cancer and autoimmune diseases. Specifically it is used to treat acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis. For acute lymphocytic leukemia it is generally used with methotrexate. It is taken by mouth.", "paragraph_text": "Mercaptopurine (6-MP), sold under the brand name Purinethol among others, is a medication used for cancer and autoimmune diseases. Specifically it is used to treat acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis. For acute lymphocytic leukemia it is generally used with methotrexate. It is taken by mouth."}, {"title": "Nicotinamide phosphoribosyltransferase As a drug target", "content": "cutaneous T-cell lymphoma (CTL), and refractory or relapsed B-chronic lymphocytic leukemia.", "is_supporting": false, "idx": 47, "question_id": "case_study_biomed/question_14.json", "text": "cutaneous T-cell lymphoma (CTL), and refractory or relapsed B-chronic lymphocytic leukemia.", "paragraph_text": "cutaneous T-cell lymphoma (CTL), and refractory or relapsed B-chronic lymphocytic leukemia."}, {"title": "Cirmtuzumab", "content": "It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).", "is_supporting": false, "idx": 48, "question_id": "case_study_biomed/question_14.json", "text": "It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL).", "paragraph_text": "It is an experimental drug in early-stage clinical trials for various cancers including chronic lymphocytic leukemia (CLL)."}, {"title": "B-cell CLL/lymphoma", "content": "Although named for B-cell chronic lymphocytic leukemia, they can be associated with other malignancies.", "is_supporting": false, "idx": 49, "question_id": "case_study_biomed/question_14.json", "text": "Although named for B-cell chronic lymphocytic leukemia, they can be associated with other malignancies.", "paragraph_text": "Although named for B-cell chronic lymphocytic leukemia, they can be associated with other malignancies."}, {"title": "Mosquito bite allergy Reactions associated with predisposing factors", "content": "Several case reports have found individuals with chronic lymphocytic leukemia are predisposed to develop severe skin reactions to mosquito and other insect bites. However, there are reports that chronic lymphocytic leukemia patients can develop similarly severe skin reactions in the absence of an insect bite history. The pathology of the insect bite sites in these cases resembles those seen in the MBA lesions of eosinophilic cellulitis but the mechanism behind these reactions is unknown. There are too few reports to establish treatment recommendations for MBA I chronic lymphocytic leukemia beyond those generally used to treat other types of MBA.", "is_supporting": false, "idx": 50, "question_id": "case_study_biomed/question_14.json", "text": "Several case reports have found individuals with chronic lymphocytic leukemia are predisposed to develop severe skin reactions to mosquito and other insect bites. However, there are reports that chronic lymphocytic leukemia patients can develop similarly severe skin reactions in the absence of an insect bite history. The pathology of the insect bite sites in these cases resembles those seen in the MBA lesions of eosinophilic cellulitis but the mechanism behind these reactions is unknown. There are too few reports to establish treatment recommendations for MBA I chronic lymphocytic leukemia beyond those generally used to treat other types of MBA.", "paragraph_text": "Several case reports have found individuals with chronic lymphocytic leukemia are predisposed to develop severe skin reactions to mosquito and other insect bites. However, there are reports that chronic lymphocytic leukemia patients can develop similarly severe skin reactions in the absence of an insect bite history. The pathology of the insect bite sites in these cases resembles those seen in the MBA lesions of eosinophilic cellulitis but the mechanism behind these reactions is unknown. There are too few reports to establish treatment recommendations for MBA I chronic lymphocytic leukemia beyond those generally used to treat other types of MBA."}, {"title": "Plasma cell dyscrasias Stages", "content": "Multiple myeloma occurring concurrently with chronic Lymphocytic Leukemia or its pre-malignant precursor, monoclonal B-cell lymphocytosis, is an extremely rare condition in which patients evidence findings of the plasma cell dyscrasia plus either one of the cited clonal lymphocytic diseases. Patients are typically elderly (median age of 74, range 42\u201391 years old) males (51 of 66 case reports) and commonly present with a combination of symptoms related to chronic lymphocytic leukemia symptoms (fatigue, autoimmune hemolytic anemia, enlargements of liver and/or spleen and lymphadenopathy) plus symptoms of multiple myelomas. Patients exhibit two distinct populations of clonal cells in their bone marrow, blood, and/or other tissues: plasma cells, which may have an immature plasmablastic morphology and small lymphocytes, which have a morphology typical of chronic lymphocytic leukemia cells. Patients blood and/or urine evidences a plasma cell-derived myeloma proteins, either IgG, IgA, or free light chain in ~50%, 20%, and 20% of cases, respectively, but may also have a second myeloma protein made by the lymphocytic cells, either an IgM or IgG. Signs and symptoms of chronic lymphocytic leukemia commonly precede those of multiple myeloma, sometimes by years. The relationship(s) between the two clones of cells in this combined disease has not been established although one study suggests that the clonal plasma cells and clonal lymphocytes arise from a common hematological stem cell. In general, patients with plasma cell myeloma with concomitant chronic Lymphocytic Leukemia/monoclonal B-cell Lymphocytosis have been treated with the same regimens used for multiple myeloma patients unless significant complications related to the lymphocytic component of their disease (e.g. autoimmune hemolytic anemia) require treatments used in chronic lymphocytic leukemia. Some patients who lack appreciable symptoms have been followed with no specific treatment of their disease.", "is_supporting": false, "idx": 51, "question_id": "case_study_biomed/question_14.json", "text": "Multiple myeloma occurring concurrently with chronic Lymphocytic Leukemia or its pre-malignant precursor, monoclonal B-cell lymphocytosis, is an extremely rare condition in which patients evidence findings of the plasma cell dyscrasia plus either one of the cited clonal lymphocytic diseases. Patients are typically elderly (median age of 74, range 42-91 years old) males (51 of 66 case reports) and commonly present with a combination of symptoms related to chronic lymphocytic leukemia symptoms (fatigue, autoimmune hemolytic anemia, enlargements of liver and/or spleen and lymphadenopathy) plus symptoms of multiple myelomas. Patients exhibit two distinct populations of clonal cells in their bone marrow, blood, and/or other tissues: plasma cells, which may have an immature plasmablastic morphology and small lymphocytes, which have a morphology typical of chronic lymphocytic leukemia cells. Patients blood and/or urine evidences a plasma cell-derived myeloma proteins, either IgG, IgA, or free light chain in ~50%, 20%, and 20% of cases, respectively, but may also have a second myeloma protein made by the lymphocytic cells, either an IgM or IgG. Signs and symptoms of chronic lymphocytic leukemia commonly precede those of multiple myeloma, sometimes by years. The relationship(s) between the two clones of cells in this combined disease has not been established although one study suggests that the clonal plasma cells and clonal lymphocytes arise from a common hematological stem cell. In general, patients with plasma cell myeloma with concomitant chronic Lymphocytic Leukemia/monoclonal B-cell Lymphocytosis have been treated with the same regimens used for multiple myeloma patients unless significant complications related to the lymphocytic component of their disease (e.g. autoimmune hemolytic anemia) require treatments used in chronic lymphocytic leukemia. Some patients who lack appreciable symptoms have been followed with no specific treatment of their disease.", "paragraph_text": "Multiple myeloma occurring concurrently with chronic Lymphocytic Leukemia or its pre-malignant precursor, monoclonal B-cell lymphocytosis, is an extremely rare condition in which patients evidence findings of the plasma cell dyscrasia plus either one of the cited clonal lymphocytic diseases. Patients are typically elderly (median age of 74, range 42-91 years old) males (51 of 66 case reports) and commonly present with a combination of symptoms related to chronic lymphocytic leukemia symptoms (fatigue, autoimmune hemolytic anemia, enlargements of liver and/or spleen and lymphadenopathy) plus symptoms of multiple myelomas. Patients exhibit two distinct populations of clonal cells in their bone marrow, blood, and/or other tissues: plasma cells, which may have an immature plasmablastic morphology and small lymphocytes, which have a morphology typical of chronic lymphocytic leukemia cells. Patients blood and/or urine evidences a plasma cell-derived myeloma proteins, either IgG, IgA, or free light chain in ~50%, 20%, and 20% of cases, respectively, but may also have a second myeloma protein made by the lymphocytic cells, either an IgM or IgG. Signs and symptoms of chronic lymphocytic leukemia commonly precede those of multiple myeloma, sometimes by years. The relationship(s) between the two clones of cells in this combined disease has not been established although one study suggests that the clonal plasma cells and clonal lymphocytes arise from a common hematological stem cell. In general, patients with plasma cell myeloma with concomitant chronic Lymphocytic Leukemia/monoclonal B-cell Lymphocytosis have been treated with the same regimens used for multiple myeloma patients unless significant complications related to the lymphocytic component of their disease (e.g. autoimmune hemolytic anemia) require treatments used in chronic lymphocytic leukemia. Some patients who lack appreciable symptoms have been followed with no specific treatment of their disease."}, {"title": "Chronic lymphocytic leukemia Epidemiology", "content": "Of all cancers involving the same class of blood cell, 7% of cases are CLL/SLL.", "is_supporting": false, "idx": 52, "question_id": "case_study_biomed/question_14.json", "text": "Of all cancers involving the same class of blood cell, 7% of cases are CLL/SLL.", "paragraph_text": "Of all cancers involving the same class of blood cell, 7% of cases are CLL/SLL."}, {"title": "CD20 Clinical significance", "content": "The anti-CD20 mAB ofatumumab (Genmab) was approved by FDA in October 2009 for chronic lymphocytic leukemia.", "is_supporting": false, "idx": 53, "question_id": "case_study_biomed/question_14.json", "text": "The anti-CD20 mAB ofatumumab (Genmab) was approved by FDA in October 2009 for chronic lymphocytic leukemia.", "paragraph_text": "The anti-CD20 mAB ofatumumab (Genmab) was approved by FDA in October 2009 for chronic lymphocytic leukemia."}, {"title": "CD20 Clinical significance", "content": "The anti-CD20 mAB obinutuzumab (Gazyva) was approved by FDA in November 2013 for chronic lymphocytic leukemia.", "is_supporting": false, "idx": 54, "question_id": "case_study_biomed/question_14.json", "text": "The anti-CD20 mAB obinutuzumab (Gazyva) was approved by FDA in November 2013 for chronic lymphocytic leukemia.", "paragraph_text": "The anti-CD20 mAB obinutuzumab (Gazyva) was approved by FDA in November 2013 for chronic lymphocytic leukemia."}, {"title": "CD180", "content": "Recently, CD180 has been demonstrated to be involved in the survival and prognosis of B-cell chronic lymphocytic leukemia.", "is_supporting": false, "idx": 55, "question_id": "case_study_biomed/question_14.json", "text": "Recently, CD180 has been demonstrated to be involved in the survival and prognosis of B-cell chronic lymphocytic leukemia.", "paragraph_text": "Recently, CD180 has been demonstrated to be involved in the survival and prognosis of B-cell chronic lymphocytic leukemia."}, {"title": "Hairy cell leukemia Prognosis", "content": "As with B-cell chronic lymphocytic leukemia, mutations in the IGHV on hairy cells are associated with better responses to initial treatments and with prolonged survival.", "is_supporting": false, "idx": 56, "question_id": "case_study_biomed/question_14.json", "text": "As with B-cell chronic lymphocytic leukemia, mutations in the IGHV on hairy cells are associated with better responses to initial treatments and with prolonged survival.", "paragraph_text": "As with B-cell chronic lymphocytic leukemia, mutations in the IGHV on hairy cells are associated with better responses to initial treatments and with prolonged survival."}, {"title": "Parkin (ligase) Function", "content": "Parkin possesses DNA binding affinity and produces a dose-dependent reduction in transcription and activity of pro-apoptotic factor p53. Transfection of p53 promoter with truncated versions of parkin into SH-SY5Y neurons revealed that parkin directly binds to the p53 promoter via its RING1 domain. Conversely, parkin may be a transcriptional target of p53 in H460 lung cells, where it mediates the tumour suppressor action of p53. Considering its role in mitochondrial homeostasis, parkin aids p53 in maintaining mitochondrial respiration while limiting glucose uptake and lactate production, thus preventing onset of the Warburg effect during tumourigenesis. Parkin further elevates cytosolic glutathione levels and protects against oxidative stress, characterising it as a critical tumour suppressor with anti-glycolytic and antioxidant capabilities.", "is_supporting": false, "idx": 57, "question_id": "case_study_biomed/question_14.json", "text": "Parkin possesses DNA binding affinity and produces a dose-dependent reduction in transcription and activity of pro-apoptotic factor p53. Transfection of p53 promoter with truncated versions of parkin into SH-SY5Y neurons revealed that parkin directly binds to the p53 promoter via its RING1 domain. Conversely, parkin may be a transcriptional target of p53 in H460 lung cells, where it mediates the tumour suppressor action of p53. Considering its role in mitochondrial homeostasis, parkin aids p53 in maintaining mitochondrial respiration while limiting glucose uptake and lactate production, thus preventing onset of the Warburg effect during tumourigenesis. Parkin further elevates cytosolic glutathione levels and protects against oxidative stress, characterising it as a critical tumour suppressor with anti-glycolytic and antioxidant capabilities.", "paragraph_text": "Parkin possesses DNA binding affinity and produces a dose-dependent reduction in transcription and activity of pro-apoptotic factor p53. Transfection of p53 promoter with truncated versions of parkin into SH-SY5Y neurons revealed that parkin directly binds to the p53 promoter via its RING1 domain. Conversely, parkin may be a transcriptional target of p53 in H460 lung cells, where it mediates the tumour suppressor action of p53. Considering its role in mitochondrial homeostasis, parkin aids p53 in maintaining mitochondrial respiration while limiting glucose uptake and lactate production, thus preventing onset of the Warburg effect during tumourigenesis. Parkin further elevates cytosolic glutathione levels and protects against oxidative stress, characterising it as a critical tumour suppressor with anti-glycolytic and antioxidant capabilities."}, {"title": "Ubiquitin ligase Mono- and poly- ubiquitylation", "content": "Monoubiquitination also can regulate cytosolic protein localization. For example, the E3 ligase MDM2 ubiquitylates p53 either for degradation (K48 polyubiquitin chain), or for nuclear export (monoubiquitylation). These events occur in a concentration dependent fashion, suggesting that modulating E3 ligase concentration is a cellular regulatory strategy for controlling protein homeostasis and localization.", "is_supporting": false, "idx": 58, "question_id": "case_study_biomed/question_14.json", "text": "Monoubiquitination also can regulate cytosolic protein localization. For example, the E3 ligase MDM2 ubiquitylates p53 either for degradation (K48 polyubiquitin chain), or for nuclear export (monoubiquitylation). These events occur in a concentration dependent fashion, suggesting that modulating E3 ligase concentration is a cellular regulatory strategy for controlling protein homeostasis and localization.", "paragraph_text": "Monoubiquitination also can regulate cytosolic protein localization. For example, the E3 ligase MDM2 ubiquitylates p53 either for degradation (K48 polyubiquitin chain), or for nuclear export (monoubiquitylation). These events occur in a concentration dependent fashion, suggesting that modulating E3 ligase concentration is a cellular regulatory strategy for controlling protein homeostasis and localization."}, {"title": "Chlorambucil Pharmacology", "content": "Gastrointestinal Distress (nausea, vomiting, diarrhea, and oral ulcerations). Central Nervous System: Seizures, tremors, muscular twitching, confusion, agitation, ataxia, and hallucinations. Skin reactions Hepatotoxicity Infertility Hair Loss Chlorambucil produces its anti-cancer effects by interfering with DNA replication and damaging the DNA in a cell. The DNA damage induces cell cycle arrest and cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bcl-2-associated X protein, an apoptosis promoter.", "is_supporting": false, "idx": 59, "question_id": "case_study_biomed/question_14.json", "text": "Gastrointestinal Distress (nausea, vomiting, diarrhea, and oral ulcerations). Central Nervous System: Seizures, tremors, muscular twitching, confusion, agitation, ataxia, and hallucinations. Skin reactions Hepatotoxicity Infertility Hair Loss Chlorambucil produces its anti-cancer effects by interfering with DNA replication and damaging the DNA in a cell. The DNA damage induces cell cycle arrest and cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bcl-2-associated X protein, an apoptosis promoter.", "paragraph_text": "Gastrointestinal Distress (nausea, vomiting, diarrhea, and oral ulcerations). Central Nervous System: Seizures, tremors, muscular twitching, confusion, agitation, ataxia, and hallucinations. Skin reactions Hepatotoxicity Infertility Hair Loss Chlorambucil produces its anti-cancer effects by interfering with DNA replication and damaging the DNA in a cell. The DNA damage induces cell cycle arrest and cellular apoptosis via the accumulation of cytosolic p53 and subsequent activation of Bcl-2-associated X protein, an apoptosis promoter."}, {"title": "P53 Role in disease", "content": "The p53 protein is continually produced and degraded in cells of healthy people, resulting in damped oscillation. The degradation of the p53 protein is associated with binding of MDM2. In a negative feedback loop, MDM2 itself is induced by the p53 protein. Mutant p53 proteins often fail to induce MDM2, causing p53 to accumulate at very high levels. Moreover, the mutant p53 protein itself can inhibit normal p53 protein levels. In some cases, single missense mutations in p53 have been shown to disrupt p53 stability and function.", "is_supporting": false, "idx": 60, "question_id": "case_study_biomed/question_14.json", "text": "The p53 protein is continually produced and degraded in cells of healthy people, resulting in damped oscillation. The degradation of the p53 protein is associated with binding of MDM2. In a negative feedback loop, MDM2 itself is induced by the p53 protein. Mutant p53 proteins often fail to induce MDM2, causing p53 to accumulate at very high levels. Moreover, the mutant p53 protein itself can inhibit normal p53 protein levels. In some cases, single missense mutations in p53 have been shown to disrupt p53 stability and function.", "paragraph_text": "The p53 protein is continually produced and degraded in cells of healthy people, resulting in damped oscillation. The degradation of the p53 protein is associated with binding of MDM2. In a negative feedback loop, MDM2 itself is induced by the p53 protein. Mutant p53 proteins often fail to induce MDM2, causing p53 to accumulate at very high levels. Moreover, the mutant p53 protein itself can inhibit normal p53 protein levels. In some cases, single missense mutations in p53 have been shown to disrupt p53 stability and function."}, {"title": "Mdm2 Ubiquitination target: p53", "content": "The key target of Mdm2 is the p53 tumor suppressor. Mdm2 has been identified as a p53 interacting protein that represses p53 transcriptional activity. Mdm2 achieves this repression by binding to and blocking the N-terminal trans-activation domain of p53. Mdm2 is a p53 responsive gene\u2014that is, its transcription can be activated by p53. Thus when p53 is stabilized, the transcription of Mdm2 is also induced, resulting in higher Mdm2 protein levels.", "is_supporting": false, "idx": 61, "question_id": "case_study_biomed/question_14.json", "text": "The key target of Mdm2 is the p53 tumor suppressor. Mdm2 has been identified as a p53 interacting protein that represses p53 transcriptional activity. Mdm2 achieves this repression by binding to and blocking the N-terminal trans-activation domain of p53. Mdm2 is a p53 responsive gene--that is, its transcription can be activated by p53. Thus when p53 is stabilized, the transcription of Mdm2 is also induced, resulting in higher Mdm2 protein levels.", "paragraph_text": "The key target of Mdm2 is the p53 tumor suppressor. Mdm2 has been identified as a p53 interacting protein that represses p53 transcriptional activity. Mdm2 achieves this repression by binding to and blocking the N-terminal trans-activation domain of p53. Mdm2 is a p53 responsive gene--that is, its transcription can be activated by p53. Thus when p53 is stabilized, the transcription of Mdm2 is also induced, resulting in higher Mdm2 protein levels."}, {"title": "Adenovirus E1B protein Functions", "content": "E1B-55k blocks p53 from inhibiting cell cycling and stops it from inducing apoptosis. Observations show that E1b-55k inhibits activation by p53 by binding a repression domain to it, converting it from an activator to a repressor of p53-activated genes. This stabilizes p53 and causes a large increase in p53 concentration. Additionally, p53 bound to E1B-55k has an affinity for its binding site that is ten times higher than free p53. Presumably, this increased affinity and concentration of p53 turns the p53-E1B-55k complex into a powerful repressor.", "is_supporting": false, "idx": 62, "question_id": "case_study_biomed/question_14.json", "text": "E1B-55k blocks p53 from inhibiting cell cycling and stops it from inducing apoptosis. Observations show that E1b-55k inhibits activation by p53 by binding a repression domain to it, converting it from an activator to a repressor of p53-activated genes. This stabilizes p53 and causes a large increase in p53 concentration. Additionally, p53 bound to E1B-55k has an affinity for its binding site that is ten times higher than free p53. Presumably, this increased affinity and concentration of p53 turns the p53-E1B-55k complex into a powerful repressor.", "paragraph_text": "E1B-55k blocks p53 from inhibiting cell cycling and stops it from inducing apoptosis. Observations show that E1b-55k inhibits activation by p53 by binding a repression domain to it, converting it from an activator to a repressor of p53-activated genes. This stabilizes p53 and causes a large increase in p53 concentration. Additionally, p53 bound to E1B-55k has an affinity for its binding site that is ten times higher than free p53. Presumably, this increased affinity and concentration of p53 turns the p53-E1B-55k complex into a powerful repressor."}, {"title": "P53 Regulation", "content": "MI-63 binds to MDM2, reactivating p53 in situations where p53's function has become inhibited.", "is_supporting": false, "idx": 63, "question_id": "case_study_biomed/question_14.json", "text": "MI-63 binds to MDM2, reactivating p53 in situations where p53's function has become inhibited.", "paragraph_text": "MI-63 binds to MDM2, reactivating p53 in situations where p53's function has become inhibited."}, {"title": "Mir-605 microRNA precursor family p53 protein network", "content": "miR-605 is transcriptionally activated by the p53 protein through interaction with the promoter region of its gene. This microRNA in turn post-transcriptionally represses the oncoprotein and p53 suppressor Mdm2, which acts with p53 in a negative feedback loop in p53-wildtype cancers. Introduction of miR-605 interrupts this p53:Mdm2 interaction and instead there is a positive feedback loop in place, enabling rapid p53 accumulation in response to stress. Such p53 accumulation induces cell cycle arrest and apoptosis.", "is_supporting": false, "idx": 64, "question_id": "case_study_biomed/question_14.json", "text": "miR-605 is transcriptionally activated by the p53 protein through interaction with the promoter region of its gene. This microRNA in turn post-transcriptionally represses the oncoprotein and p53 suppressor Mdm2, which acts with p53 in a negative feedback loop in p53-wildtype cancers. Introduction of miR-605 interrupts this p53:Mdm2 interaction and instead there is a positive feedback loop in place, enabling rapid p53 accumulation in response to stress. Such p53 accumulation induces cell cycle arrest and apoptosis.", "paragraph_text": "miR-605 is transcriptionally activated by the p53 protein through interaction with the promoter region of its gene. This microRNA in turn post-transcriptionally represses the oncoprotein and p53 suppressor Mdm2, which acts with p53 in a negative feedback loop in p53-wildtype cancers. Introduction of miR-605 interrupts this p53:Mdm2 interaction and instead there is a positive feedback loop in place, enabling rapid p53 accumulation in response to stress. Such p53 accumulation induces cell cycle arrest and apoptosis."}, {"title": "MDC1 Function", "content": "MDC1 has anti-apoptotic properties by directly inhibiting the apoptotic activity of the tumor suppressing protein p53. DNA damage can induce apoptosis when the ATM kinase and Chk2 phosphorylate p53 on its Ser-15 and Ser-20 residues which activates p53 and stabilizes it by allowing it to dissociate from the E3 ubiquitin protein ligase MDM2. MDC1 can execute its anti-apoptotic activity by inhibiting p53 in two ways. The MDC1 protein can bind to the n-terminus of p53 through its BRC1 domain which blocks p53 transactivation domain. MDC1 can also inactivate p53 by reducing the phosphorylation levels of p53 Ser-15 residues necessary to p53 apoptotic activity.", "is_supporting": false, "idx": 65, "question_id": "case_study_biomed/question_14.json", "text": "MDC1 has anti-apoptotic properties by directly inhibiting the apoptotic activity of the tumor suppressing protein p53. DNA damage can induce apoptosis when the ATM kinase and Chk2 phosphorylate p53 on its Ser-15 and Ser-20 residues which activates p53 and stabilizes it by allowing it to dissociate from the E3 ubiquitin protein ligase MDM2. MDC1 can execute its anti-apoptotic activity by inhibiting p53 in two ways. The MDC1 protein can bind to the n-terminus of p53 through its BRC1 domain which blocks p53 transactivation domain. MDC1 can also inactivate p53 by reducing the phosphorylation levels of p53 Ser-15 residues necessary to p53 apoptotic activity.", "paragraph_text": "MDC1 has anti-apoptotic properties by directly inhibiting the apoptotic activity of the tumor suppressing protein p53. DNA damage can induce apoptosis when the ATM kinase and Chk2 phosphorylate p53 on its Ser-15 and Ser-20 residues which activates p53 and stabilizes it by allowing it to dissociate from the E3 ubiquitin protein ligase MDM2. MDC1 can execute its anti-apoptotic activity by inhibiting p53 in two ways. The MDC1 protein can bind to the n-terminus of p53 through its BRC1 domain which blocks p53 transactivation domain. MDC1 can also inactivate p53 by reducing the phosphorylation levels of p53 Ser-15 residues necessary to p53 apoptotic activity."}, {"title": "P53 Regulation", "content": "In unstressed cells, p53 levels are kept low through a continuous degradation of p53. A protein called Mdm2 (also called HDM2 in humans), binds to p53, preventing its action and transports it from the nucleus to the cytosol. Mdm2 also acts as an ubiquitin ligase and covalently attaches ubiquitin to p53 and thus marks p53 for degradation by the proteasome. However, ubiquitylation of p53 is reversible. On activation of p53, Mdm2 is also activated, setting up a feedback loop. p53 levels can show oscillations (or repeated pulses) in response to certain stresses, and these pulses can be important in determining whether the cells survive the stress, or die.", "is_supporting": false, "idx": 66, "question_id": "case_study_biomed/question_14.json", "text": "In unstressed cells, p53 levels are kept low through a continuous degradation of p53. A protein called Mdm2 (also called HDM2 in humans), binds to p53, preventing its action and transports it from the nucleus to the cytosol. Mdm2 also acts as an ubiquitin ligase and covalently attaches ubiquitin to p53 and thus marks p53 for degradation by the proteasome. However, ubiquitylation of p53 is reversible. On activation of p53, Mdm2 is also activated, setting up a feedback loop. p53 levels can show oscillations (or repeated pulses) in response to certain stresses, and these pulses can be important in determining whether the cells survive the stress, or die.", "paragraph_text": "In unstressed cells, p53 levels are kept low through a continuous degradation of p53. A protein called Mdm2 (also called HDM2 in humans), binds to p53, preventing its action and transports it from the nucleus to the cytosol. Mdm2 also acts as an ubiquitin ligase and covalently attaches ubiquitin to p53 and thus marks p53 for degradation by the proteasome. However, ubiquitylation of p53 is reversible. On activation of p53, Mdm2 is also activated, setting up a feedback loop. p53 levels can show oscillations (or repeated pulses) in response to certain stresses, and these pulses can be important in determining whether the cells survive the stress, or die."}, {"title": "P53 Experimental analysis of p53 mutations", "content": "citation needed] The dynamics of p53 proteins, along with its antagonist Mdm2, indicate that the levels of p53, in units of concentration, oscillate as a function of time. This \"damped\" oscillation is both clinically documented and mathematically modelled. Mathematical models also indicate that the p53 concentration oscillates much faster once teratogens, such as double-stranded breaks (DSB) or UV radiation, are introduced to the system. This supports and models the current understanding of p53 dynamics, where DNA damage induces p53 activation (see p53 regulation for more information). Current models can also be useful for modelling the mutations in p53 isoforms and their effects on p53 oscillation, thereby promoting de novo tissue-specific pharmacological drug discovery.", "is_supporting": false, "idx": 67, "question_id": "case_study_biomed/question_14.json", "text": "citation needed] The dynamics of p53 proteins, along with its antagonist Mdm2, indicate that the levels of p53, in units of concentration, oscillate as a function of time. This \"damped\" oscillation is both clinically documented and mathematically modelled. Mathematical models also indicate that the p53 concentration oscillates much faster once teratogens, such as double-stranded breaks (DSB) or UV radiation, are introduced to the system. This supports and models the current understanding of p53 dynamics, where DNA damage induces p53 activation (see p53 regulation for more information). Current models can also be useful for modelling the mutations in p53 isoforms and their effects on p53 oscillation, thereby promoting de novo tissue-specific pharmacological drug discovery.", "paragraph_text": "citation needed] The dynamics of p53 proteins, along with its antagonist Mdm2, indicate that the levels of p53, in units of concentration, oscillate as a function of time. This \"damped\" oscillation is both clinically documented and mathematically modelled. Mathematical models also indicate that the p53 concentration oscillates much faster once teratogens, such as double-stranded breaks (DSB) or UV radiation, are introduced to the system. This supports and models the current understanding of p53 dynamics, where DNA damage induces p53 activation (see p53 regulation for more information). Current models can also be useful for modelling the mutations in p53 isoforms and their effects on p53 oscillation, thereby promoting de novo tissue-specific pharmacological drug discovery."}, {"title": "Ribosomopathy p53", "content": "The p53 pathway is central to the ribosomopathy phenotype. Ribosomal stress triggers activation of the p53 signaling pathway.", "is_supporting": false, "idx": 68, "question_id": "case_study_biomed/question_14.json", "text": "The p53 pathway is central to the ribosomopathy phenotype. Ribosomal stress triggers activation of the p53 signaling pathway.", "paragraph_text": "The p53 pathway is central to the ribosomopathy phenotype. Ribosomal stress triggers activation of the p53 signaling pathway."}, {"title": "Neutrophil cytosolic factor 4 Interactions", "content": "Neutrophil cytosolic factor 4 has been shown to interact with Ku70, Neutrophil cytosolic factor 1 and Moesin.", "is_supporting": false, "idx": 69, "question_id": "case_study_biomed/question_14.json", "text": "Neutrophil cytosolic factor 4 has been shown to interact with Ku70, Neutrophil cytosolic factor 1 and Moesin.", "paragraph_text": "Neutrophil cytosolic factor 4 has been shown to interact with Ku70, Neutrophil cytosolic factor 1 and Moesin."}, {"title": "P53 (disambiguation)", "content": "P53 may also refer to:", "is_supporting": false, "idx": 70, "question_id": "case_study_biomed/question_14.json", "text": "P53 may also refer to:", "paragraph_text": "P53 may also refer to:"}, {"title": "P53 p63 p73 family", "content": "It consists of: p53 TP73L (also known as \"p63\") p73 They are sometimes considered part of a \"p53 family\".", "is_supporting": false, "idx": 71, "question_id": "case_study_biomed/question_14.json", "text": "It consists of: p53 TP73L (also known as \"p63\") p73 They are sometimes considered part of a \"p53 family\".", "paragraph_text": "It consists of: p53 TP73L (also known as \"p63\") p73 They are sometimes considered part of a \"p53 family\"."}, {"title": "P53 (disambiguation)", "content": "p53 is a tumor suppressor protein.", "is_supporting": false, "idx": 72, "question_id": "case_study_biomed/question_14.json", "text": "p53 is a tumor suppressor protein.", "paragraph_text": "p53 is a tumor suppressor protein."}, {"title": "MUC1 Role in cancer", "content": "MUC1 cytoplasmic tail has been shown to bind to p53. This interaction is increased by genotoxic stress. MUC1 and p53 were found to be associated with the p53 response element of the p21 gene promoter. This results in activation of p21 which results in cell cycle arrest. Association of MUC1 with p53 in cancer results in inhibition of p53-mediated apoptosis and promotion of p53-mediated cell cycle arrest.", "is_supporting": false, "idx": 73, "question_id": "case_study_biomed/question_14.json", "text": "MUC1 cytoplasmic tail has been shown to bind to p53. This interaction is increased by genotoxic stress. MUC1 and p53 were found to be associated with the p53 response element of the p21 gene promoter. This results in activation of p21 which results in cell cycle arrest. Association of MUC1 with p53 in cancer results in inhibition of p53-mediated apoptosis and promotion of p53-mediated cell cycle arrest.", "paragraph_text": "MUC1 cytoplasmic tail has been shown to bind to p53. This interaction is increased by genotoxic stress. MUC1 and p53 were found to be associated with the p53 response element of the p21 gene promoter. This results in activation of p21 which results in cell cycle arrest. Association of MUC1 with p53 in cancer results in inhibition of p53-mediated apoptosis and promotion of p53-mediated cell cycle arrest."}, {"title": "P53 upregulated modulator of apoptosis Role in cancer", "content": "PUMA can also function as an indicator of p53 mutations. Many cancers exhibit mutations in the p53 gene, but this mutation can only be detected through extensive DNA sequencing. Studies have shown that cells with p53 mutations have significantly lower levels of PUMA, making it a good candidate for a protein marker of p53 mutations, providing a simpler method for testing for p53 mutations.", "is_supporting": false, "idx": 74, "question_id": "case_study_biomed/question_14.json", "text": "PUMA can also function as an indicator of p53 mutations. Many cancers exhibit mutations in the p53 gene, but this mutation can only be detected through extensive DNA sequencing. Studies have shown that cells with p53 mutations have significantly lower levels of PUMA, making it a good candidate for a protein marker of p53 mutations, providing a simpler method for testing for p53 mutations.", "paragraph_text": "PUMA can also function as an indicator of p53 mutations. Many cancers exhibit mutations in the p53 gene, but this mutation can only be detected through extensive DNA sequencing. Studies have shown that cells with p53 mutations have significantly lower levels of PUMA, making it a good candidate for a protein marker of p53 mutations, providing a simpler method for testing for p53 mutations."}, {"title": "USP7 Function", "content": "HAUSP is most popularly known as a direct antagonist of Mdm2, the E3 ubiquitin ligase for the tumor suppressor protein, p53. Normally, p53 levels are kept low in part due to Mdm2-mediated ubiquitylation and degradation of p53. In response to oncogenic insults, HAUSP can deubiquitinate p53 and protect p53 from Mdm2-mediated degradation, indicating that it may possess a tumor suppressor function for the immediate stabilization of p53 in response to stress.", "is_supporting": false, "idx": 75, "question_id": "case_study_biomed/question_14.json", "text": "HAUSP is most popularly known as a direct antagonist of Mdm2, the E3 ubiquitin ligase for the tumor suppressor protein, p53. Normally, p53 levels are kept low in part due to Mdm2-mediated ubiquitylation and degradation of p53. In response to oncogenic insults, HAUSP can deubiquitinate p53 and protect p53 from Mdm2-mediated degradation, indicating that it may possess a tumor suppressor function for the immediate stabilization of p53 in response to stress.", "paragraph_text": "HAUSP is most popularly known as a direct antagonist of Mdm2, the E3 ubiquitin ligase for the tumor suppressor protein, p53. Normally, p53 levels are kept low in part due to Mdm2-mediated ubiquitylation and degradation of p53. In response to oncogenic insults, HAUSP can deubiquitinate p53 and protect p53 from Mdm2-mediated degradation, indicating that it may possess a tumor suppressor function for the immediate stabilization of p53 in response to stress."}, {"title": "Mdm2 E3 ligase activity", "content": "The E3 ubiquitin ligase MDM2 is a negative regulator of the p53 tumor suppressor protein. MDM2 binds and ubiquitinates p53, facilitating it for degradation. p53 can induce transcription of MDM2, generating a negative feedback loop. Mdm2 also acts as an E3 ubiquitin ligase, targeting both itself and p53 for degradation by the proteasome (see also ubiquitin). Several lysine residues in p53 C-terminus have been identified as the sites of ubiquitination, and it has been shown that p53 protein levels are downregulated by Mdm2 in a proteasome-dependent manner. Mdm2 is capable of auto-polyubiquitination, and in complex with p300, a cooperating E3 ubiquitin ligase, is capable of polyubiquitinating p53. In this manner, Mdm2 and p53 are the members of a negative feedback control loop that keeps the level of p53 low in the absence of p53-stabilizing signals. This loop can be interfered with by kinases and genes like p14arf when p53 activation signals, including DNA damage, are high.", "is_supporting": false, "idx": 76, "question_id": "case_study_biomed/question_14.json", "text": "The E3 ubiquitin ligase MDM2 is a negative regulator of the p53 tumor suppressor protein. MDM2 binds and ubiquitinates p53, facilitating it for degradation. p53 can induce transcription of MDM2, generating a negative feedback loop. Mdm2 also acts as an E3 ubiquitin ligase, targeting both itself and p53 for degradation by the proteasome (see also ubiquitin). Several lysine residues in p53 C-terminus have been identified as the sites of ubiquitination, and it has been shown that p53 protein levels are downregulated by Mdm2 in a proteasome-dependent manner. Mdm2 is capable of auto-polyubiquitination, and in complex with p300, a cooperating E3 ubiquitin ligase, is capable of polyubiquitinating p53. In this manner, Mdm2 and p53 are the members of a negative feedback control loop that keeps the level of p53 low in the absence of p53-stabilizing signals. This loop can be interfered with by kinases and genes like p14arf when p53 activation signals, including DNA damage, are high.", "paragraph_text": "The E3 ubiquitin ligase MDM2 is a negative regulator of the p53 tumor suppressor protein. MDM2 binds and ubiquitinates p53, facilitating it for degradation. p53 can induce transcription of MDM2, generating a negative feedback loop. Mdm2 also acts as an E3 ubiquitin ligase, targeting both itself and p53 for degradation by the proteasome (see also ubiquitin). Several lysine residues in p53 C-terminus have been identified as the sites of ubiquitination, and it has been shown that p53 protein levels are downregulated by Mdm2 in a proteasome-dependent manner. Mdm2 is capable of auto-polyubiquitination, and in complex with p300, a cooperating E3 ubiquitin ligase, is capable of polyubiquitinating p53. In this manner, Mdm2 and p53 are the members of a negative feedback control loop that keeps the level of p53 low in the absence of p53-stabilizing signals. This loop can be interfered with by kinases and genes like p14arf when p53 activation signals, including DNA damage, are high."}, {"title": "P53 Function", "content": "p53 expression can be stimulated by UV light, which also causes DNA damage. In this case, p53 can initiate events leading to tanning.", "is_supporting": false, "idx": 77, "question_id": "case_study_biomed/question_14.json", "text": "p53 expression can be stimulated by UV light, which also causes DNA damage. In this case, p53 can initiate events leading to tanning.", "paragraph_text": "p53 expression can be stimulated by UV light, which also causes DNA damage. In this case, p53 can initiate events leading to tanning."}, {"title": "P53 Interactions", "content": "p53 has been shown to interact with:", "is_supporting": false, "idx": 78, "question_id": "case_study_biomed/question_14.json", "text": "p53 has been shown to interact with:", "paragraph_text": "p53 has been shown to interact with:"}, {"title": "P53 Regulation", "content": "A ubiquitin specific protease, USP7 (or HAUSP), can cleave ubiquitin off p53, thereby protecting it from proteasome-dependent degradation via the ubiquitin ligase pathway . This is one means by which p53 is stabilized in response to oncogenic insults. USP42 has also been shown to deubiquitinate p53 and may be required for the ability of p53 to respond to stress.", "is_supporting": false, "idx": 79, "question_id": "case_study_biomed/question_14.json", "text": "A ubiquitin specific protease, USP7 (or HAUSP), can cleave ubiquitin off p53, thereby protecting it from proteasome-dependent degradation via the ubiquitin ligase pathway . This is one means by which p53 is stabilized in response to oncogenic insults. USP42 has also been shown to deubiquitinate p53 and may be required for the ability of p53 to respond to stress.", "paragraph_text": "A ubiquitin specific protease, USP7 (or HAUSP), can cleave ubiquitin off p53, thereby protecting it from proteasome-dependent degradation via the ubiquitin ligase pathway . This is one means by which p53 is stabilized in response to oncogenic insults. USP42 has also been shown to deubiquitinate p53 and may be required for the ability of p53 to respond to stress."}, {"title": "TP63", "content": "The TP63 gene was discovered 20 years after the discovery of the p53 tumor suppressor gene and along with p73 constitutes the p53 gene family based on their structural similarity. Despite being discovered significantly later than p53, phylogenetic analysis of p53, p63 and p73, suggest that p63 was the original member of the family from which p53 and p73 evolved.", "is_supporting": false, "idx": 80, "question_id": "case_study_biomed/question_14.json", "text": "The TP63 gene was discovered 20 years after the discovery of the p53 tumor suppressor gene and along with p73 constitutes the p53 gene family based on their structural similarity. Despite being discovered significantly later than p53, phylogenetic analysis of p53, p63 and p73, suggest that p63 was the original member of the family from which p53 and p73 evolved.", "paragraph_text": "The TP63 gene was discovered 20 years after the discovery of the p53 tumor suppressor gene and along with p73 constitutes the p53 gene family based on their structural similarity. Despite being discovered significantly later than p53, phylogenetic analysis of p53, p63 and p73, suggest that p63 was the original member of the family from which p53 and p73 evolved."}, {"title": "Gendicine", "content": "Gendicine is a recombinant adenovirus engineered to express wildtype-p53 (rAd-p53). This virus is designed to treat patients with tumors which have mutated p53 genes.", "is_supporting": false, "idx": 81, "question_id": "case_study_biomed/question_14.json", "text": "Gendicine is a recombinant adenovirus engineered to express wildtype-p53 (rAd-p53). This virus is designed to treat patients with tumors which have mutated p53 genes.", "paragraph_text": "Gendicine is a recombinant adenovirus engineered to express wildtype-p53 (rAd-p53). This virus is designed to treat patients with tumors which have mutated p53 genes."}, {"title": "C-jun Function", "content": "In cells absent of c-jun, the expression of p53 (cell cycle arrest inducer) and p21 (CDK inhibitor and p53 target gene) is increased, and those cells exhibit cell cycle defect. Overexpression of c-jun in cells results in decreased level of p53 and p21, and exhibits accelerated cell proliferation. C-jun represses p53 transcription by binding to a variant AP-1 site in the p53 promoter. Those results indicate that c-jun downregulates p53 to control cell cycle progression.", "is_supporting": false, "idx": 82, "question_id": "case_study_biomed/question_14.json", "text": "In cells absent of c-jun, the expression of p53 (cell cycle arrest inducer) and p21 (CDK inhibitor and p53 target gene) is increased, and those cells exhibit cell cycle defect. Overexpression of c-jun in cells results in decreased level of p53 and p21, and exhibits accelerated cell proliferation. C-jun represses p53 transcription by binding to a variant AP-1 site in the p53 promoter. Those results indicate that c-jun downregulates p53 to control cell cycle progression.", "paragraph_text": "In cells absent of c-jun, the expression of p53 (cell cycle arrest inducer) and p21 (CDK inhibitor and p53 target gene) is increased, and those cells exhibit cell cycle defect. Overexpression of c-jun in cells results in decreased level of p53 and p21, and exhibits accelerated cell proliferation. C-jun represses p53 transcription by binding to a variant AP-1 site in the p53 promoter. Those results indicate that c-jun downregulates p53 to control cell cycle progression."}, {"title": "Ifi202", "content": "Using in B6.Nba2 lupus susceptible mice as the animal model, researchers were able to show increased expression of Ifi202 inhibits p53-mediated apoptosis of splenic B cells. Since it is known that p53 mediates the expression of proapoptotic proteins, the increased p202 correlates with increased p53 levels. p202 seems to bind to p53 protein in the N-terminal region to inhibit p53 function.", "is_supporting": false, "idx": 83, "question_id": "case_study_biomed/question_14.json", "text": "Using in B6.Nba2 lupus susceptible mice as the animal model, researchers were able to show increased expression of Ifi202 inhibits p53-mediated apoptosis of splenic B cells. Since it is known that p53 mediates the expression of proapoptotic proteins, the increased p202 correlates with increased p53 levels. p202 seems to bind to p53 protein in the N-terminal region to inhibit p53 function.", "paragraph_text": "Using in B6.Nba2 lupus susceptible mice as the animal model, researchers were able to show increased expression of Ifi202 inhibits p53-mediated apoptosis of splenic B cells. Since it is known that p53 mediates the expression of proapoptotic proteins, the increased p202 correlates with increased p53 levels. p202 seems to bind to p53 protein in the N-terminal region to inhibit p53 function."}, {"title": "Acetylation Protein acetylation", "content": "Since the major function of p53 is tumor suppressor, the idea that activation of p53 is an appealing strategy for cancer treatment. Nutlin-3 is a small molecule designed to target p53 and Mdm2 interaction that kept p53 from deactivation. Reports also shown that the cancer cell under the Nutilin-3a treatment, acetylation of lys 382 was observed in the c-terminal of p53.", "is_supporting": false, "idx": 84, "question_id": "case_study_biomed/question_14.json", "text": "Since the major function of p53 is tumor suppressor, the idea that activation of p53 is an appealing strategy for cancer treatment. Nutlin-3 is a small molecule designed to target p53 and Mdm2 interaction that kept p53 from deactivation. Reports also shown that the cancer cell under the Nutilin-3a treatment, acetylation of lys 382 was observed in the c-terminal of p53.", "paragraph_text": "Since the major function of p53 is tumor suppressor, the idea that activation of p53 is an appealing strategy for cancer treatment. Nutlin-3 is a small molecule designed to target p53 and Mdm2 interaction that kept p53 from deactivation. Reports also shown that the cancer cell under the Nutilin-3a treatment, acetylation of lys 382 was observed in the c-terminal of p53."}, {"title": "Nutlin", "content": "Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumor suppressor p53, and which were discovered by screening a chemical library by Vassilev et al. Nutlin-1, nutlin-2, and nutlin-3 were all identified in the same screen; however, Nutlin-3 is the compound most commonly used in anti-cancer studies. Nutlin small molecules occupy p53 binding pocket of MDM2 and effectively disrupt the p53\u2013MDM2 interaction that leads to activation of the p53 pathway in p53 wild-type cells. Inhibiting the interaction between mdm2 and p53 stabilizes p53, and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or \"wild-type\" p53.[citation needed] Nutlin-3 has been shown to affect the production of p53 within minutes.", "is_supporting": false, "idx": 85, "question_id": "case_study_biomed/question_14.json", "text": "Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumor suppressor p53, and which were discovered by screening a chemical library by Vassilev et al. Nutlin-1, nutlin-2, and nutlin-3 were all identified in the same screen; however, Nutlin-3 is the compound most commonly used in anti-cancer studies. Nutlin small molecules occupy p53 binding pocket of MDM2 and effectively disrupt the p53-MDM2 interaction that leads to activation of the p53 pathway in p53 wild-type cells. Inhibiting the interaction between mdm2 and p53 stabilizes p53, and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or \"wild-type\" p53.[citation needed] Nutlin-3 has been shown to affect the production of p53 within minutes.", "paragraph_text": "Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumor suppressor p53, and which were discovered by screening a chemical library by Vassilev et al. Nutlin-1, nutlin-2, and nutlin-3 were all identified in the same screen; however, Nutlin-3 is the compound most commonly used in anti-cancer studies. Nutlin small molecules occupy p53 binding pocket of MDM2 and effectively disrupt the p53-MDM2 interaction that leads to activation of the p53 pathway in p53 wild-type cells. Inhibiting the interaction between mdm2 and p53 stabilizes p53, and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or \"wild-type\" p53.[citation needed] Nutlin-3 has been shown to affect the production of p53 within minutes."}, {"title": "P53 Function", "content": "In human embryonic stem cells (hESCs)s, p53 is maintained at low inactive levels. This is because activation of p53 leads to rapid differentiation of hESCs. Studies have shown that knocking out p53 delays differentiation and that adding p53 causes spontaneous differentiation, showing how p53 promotes differentiation of hESCs and plays a key role in cell cycle as a differentiation regulator. When p53 becomes stabilized and activated in hESCs, it increases p21 to establish a longer G1. This typically leads to abolition of S-phase entry, which stops the cell cycle in G1, leading to differentiation. Work in mouse embryonic stem cells has recently shown however that the expression of P53 does not necessarily lead to differentiation. p53 also activates miR-34a and miR-145, which then repress the hESCs pluripotency factors, further instigating differentiation.", "is_supporting": false, "idx": 86, "question_id": "case_study_biomed/question_14.json", "text": "In human embryonic stem cells (hESCs)s, p53 is maintained at low inactive levels. This is because activation of p53 leads to rapid differentiation of hESCs. Studies have shown that knocking out p53 delays differentiation and that adding p53 causes spontaneous differentiation, showing how p53 promotes differentiation of hESCs and plays a key role in cell cycle as a differentiation regulator. When p53 becomes stabilized and activated in hESCs, it increases p21 to establish a longer G1. This typically leads to abolition of S-phase entry, which stops the cell cycle in G1, leading to differentiation. Work in mouse embryonic stem cells has recently shown however that the expression of P53 does not necessarily lead to differentiation. p53 also activates miR-34a and miR-145, which then repress the hESCs pluripotency factors, further instigating differentiation.", "paragraph_text": "In human embryonic stem cells (hESCs)s, p53 is maintained at low inactive levels. This is because activation of p53 leads to rapid differentiation of hESCs. Studies have shown that knocking out p53 delays differentiation and that adding p53 causes spontaneous differentiation, showing how p53 promotes differentiation of hESCs and plays a key role in cell cycle as a differentiation regulator. When p53 becomes stabilized and activated in hESCs, it increases p21 to establish a longer G1. This typically leads to abolition of S-phase entry, which stops the cell cycle in G1, leading to differentiation. Work in mouse embryonic stem cells has recently shown however that the expression of P53 does not necessarily lead to differentiation. p53 also activates miR-34a and miR-145, which then repress the hESCs pluripotency factors, further instigating differentiation."}, {"title": "Survivin Regulation by p53", "content": "Wild-type p53 has been shown to repress survivin expression at the mRNA level. Using an adenovirus vector for wild-type p53, human ovarian cancer cell line 2774qw1 (which expresses mutant p53) was transfected. mRNA levels of survivin were analyzed by real-time quantitative PCR (RT-PCR) and showed time-dependent down regulation of survivin mRNA levels when the cells were infected with wild-type p53. A 3.6 fold decrease of survivin mRNA level was observed 16 hours after infection initiation and decreased 6.7 fold 24 hours after infection. Western blot results do show that there is indeed the p53 from the adenoviral vector was being expressed in the cells using antibody specific for p53. The expression of p53 levels indicative of its role in survivin repression shows that p53 started to be expressed 6 hours into infection and had its highest level at 16\u201324 hours. To further confirm that endogenous wild-type p53 is really causing the repression of survivin gene expression, the authors induced A549 (human lung cancer cell line with wild-type p53) and T47D (human breast cancer cell line with mutant p53) cells with DNA-damaging agent adriamycin to trigger the physiological p53 apoptotic response in these cancer cells and compare the survivin levels measured to the same cells without DNA damage induction. The A549 line, which intrinsically has functioning wild-type p53, showed significant reduction in survivin levels compared to non-induced cells. This same effect was not seen in T47D cells that carry mutant inactive p53.", "is_supporting": false, "idx": 87, "question_id": "case_study_biomed/question_14.json", "text": "Wild-type p53 has been shown to repress survivin expression at the mRNA level. Using an adenovirus vector for wild-type p53, human ovarian cancer cell line 2774qw1 (which expresses mutant p53) was transfected. mRNA levels of survivin were analyzed by real-time quantitative PCR (RT-PCR) and showed time-dependent down regulation of survivin mRNA levels when the cells were infected with wild-type p53. A 3.6 fold decrease of survivin mRNA level was observed 16 hours after infection initiation and decreased 6.7 fold 24 hours after infection. Western blot results do show that there is indeed the p53 from the adenoviral vector was being expressed in the cells using antibody specific for p53. The expression of p53 levels indicative of its role in survivin repression shows that p53 started to be expressed 6 hours into infection and had its highest level at 16-24 hours. To further confirm that endogenous wild-type p53 is really causing the repression of survivin gene expression, the authors induced A549 (human lung cancer cell line with wild-type p53) and T47D (human breast cancer cell line with mutant p53) cells with DNA-damaging agent adriamycin to trigger the physiological p53 apoptotic response in these cancer cells and compare the survivin levels measured to the same cells without DNA damage induction. The A549 line, which intrinsically has functioning wild-type p53, showed significant reduction in survivin levels compared to non-induced cells. This same effect was not seen in T47D cells that carry mutant inactive p53.", "paragraph_text": "Wild-type p53 has been shown to repress survivin expression at the mRNA level. Using an adenovirus vector for wild-type p53, human ovarian cancer cell line 2774qw1 (which expresses mutant p53) was transfected. mRNA levels of survivin were analyzed by real-time quantitative PCR (RT-PCR) and showed time-dependent down regulation of survivin mRNA levels when the cells were infected with wild-type p53. A 3.6 fold decrease of survivin mRNA level was observed 16 hours after infection initiation and decreased 6.7 fold 24 hours after infection. Western blot results do show that there is indeed the p53 from the adenoviral vector was being expressed in the cells using antibody specific for p53. The expression of p53 levels indicative of its role in survivin repression shows that p53 started to be expressed 6 hours into infection and had its highest level at 16-24 hours. To further confirm that endogenous wild-type p53 is really causing the repression of survivin gene expression, the authors induced A549 (human lung cancer cell line with wild-type p53) and T47D (human breast cancer cell line with mutant p53) cells with DNA-damaging agent adriamycin to trigger the physiological p53 apoptotic response in these cancer cells and compare the survivin levels measured to the same cells without DNA damage induction. The A549 line, which intrinsically has functioning wild-type p53, showed significant reduction in survivin levels compared to non-induced cells. This same effect was not seen in T47D cells that carry mutant inactive p53."}, {"title": "P53 Regulation", "content": "Phosphorylation of the N-terminal end of p53 by the above-mentioned protein kinases disrupts Mdm2-binding. Other proteins, such as Pin1, are then recruited to p53 and induce a conformational change in p53, which prevents Mdm2-binding even more. Phosphorylation also allows for binding of transcriptional coactivators, like p300 and PCAF, which then acetylate the carboxy-terminal end of p53, exposing the DNA binding domain of p53, allowing it to activate or repress specific genes. Deacetylase enzymes, such as Sirt1 and Sirt7, can deacetylate p53, leading to an inhibition of apoptosis. Some oncogenes can also stimulate the transcription of proteins that bind to MDM2 and inhibit its activity.", "is_supporting": false, "idx": 88, "question_id": "case_study_biomed/question_14.json", "text": "Phosphorylation of the N-terminal end of p53 by the above-mentioned protein kinases disrupts Mdm2-binding. Other proteins, such as Pin1, are then recruited to p53 and induce a conformational change in p53, which prevents Mdm2-binding even more. Phosphorylation also allows for binding of transcriptional coactivators, like p300 and PCAF, which then acetylate the carboxy-terminal end of p53, exposing the DNA binding domain of p53, allowing it to activate or repress specific genes. Deacetylase enzymes, such as Sirt1 and Sirt7, can deacetylate p53, leading to an inhibition of apoptosis. Some oncogenes can also stimulate the transcription of proteins that bind to MDM2 and inhibit its activity.", "paragraph_text": "Phosphorylation of the N-terminal end of p53 by the above-mentioned protein kinases disrupts Mdm2-binding. Other proteins, such as Pin1, are then recruited to p53 and induce a conformational change in p53, which prevents Mdm2-binding even more. Phosphorylation also allows for binding of transcriptional coactivators, like p300 and PCAF, which then acetylate the carboxy-terminal end of p53, exposing the DNA binding domain of p53, allowing it to activate or repress specific genes. Deacetylase enzymes, such as Sirt1 and Sirt7, can deacetylate p53, leading to an inhibition of apoptosis. Some oncogenes can also stimulate the transcription of proteins that bind to MDM2 and inhibit its activity."}, {"title": "DNA damage (naturally occurring) p53 role in DNA damage repair system", "content": "p53 is a major key player in the growth of cancerous cells. Damaged DNA cells with mutated p53 are at a higher risk of becoming cancerous. Common chemotherapy treatments are genotoxic. These treatments are ineffective in cancer tumor that have mutated p53 since they do not have a functioning p53 to either arrest or kill the damaged cell.", "is_supporting": false, "idx": 89, "question_id": "case_study_biomed/question_14.json", "text": "p53 is a major key player in the growth of cancerous cells. Damaged DNA cells with mutated p53 are at a higher risk of becoming cancerous. Common chemotherapy treatments are genotoxic. These treatments are ineffective in cancer tumor that have mutated p53 since they do not have a functioning p53 to either arrest or kill the damaged cell.", "paragraph_text": "p53 is a major key player in the growth of cancerous cells. Damaged DNA cells with mutated p53 are at a higher risk of becoming cancerous. Common chemotherapy treatments are genotoxic. These treatments are ineffective in cancer tumor that have mutated p53 since they do not have a functioning p53 to either arrest or kill the damaged cell."}, {"title": "Lymphocyte cytosolic protein 2 Interactions", "content": "Lymphocyte cytosolic protein 2 has been shown to interact with:", "is_supporting": false, "idx": 90, "question_id": "case_study_biomed/question_14.json", "text": "Lymphocyte cytosolic protein 2 has been shown to interact with:", "paragraph_text": "Lymphocyte cytosolic protein 2 has been shown to interact with:"}, {"title": "Neutrophil cytosolic factor 1 Interactions", "content": "Neutrophil cytosolic factor 1 has been shown to interact with:", "is_supporting": false, "idx": 91, "question_id": "case_study_biomed/question_14.json", "text": "Neutrophil cytosolic factor 1 has been shown to interact with:", "paragraph_text": "Neutrophil cytosolic factor 1 has been shown to interact with:"}, {"title": "P53 Discovery", "content": "In 1993, p53 was voted molecule of the year by Science magazine.", "is_supporting": false, "idx": 92, "question_id": "case_study_biomed/question_14.json", "text": "In 1993, p53 was voted molecule of the year by Science magazine.", "paragraph_text": "In 1993, p53 was voted molecule of the year by Science magazine."}, {"title": "Bcl-2-associated X protein Clinical significance", "content": "The expression of BAX is upregulated by the tumor suppressor protein p53, and BAX has been shown to be involved in p53-mediated apoptosis. The p53 protein is a transcription factor that, when activated as part of the cell's response to stress, regulates many downstream target genes, including BAX. Wild-type p53 has been demonstrated to upregulate the transcription of a chimeric reporter plasmid utilizing the consensus promoter sequence of BAX approximately 50-fold over mutant p53. Thus it is likely that p53 promotes BAX's apoptotic faculties in vivo as a primary transcription factor. However, p53 also has a transcription-independent role in apoptosis. In particular, p53 interacts with BAX, promoting its activation as well as its insertion into the mitochondrial membrane.", "is_supporting": false, "idx": 93, "question_id": "case_study_biomed/question_14.json", "text": "The expression of BAX is upregulated by the tumor suppressor protein p53, and BAX has been shown to be involved in p53-mediated apoptosis. The p53 protein is a transcription factor that, when activated as part of the cell's response to stress, regulates many downstream target genes, including BAX. Wild-type p53 has been demonstrated to upregulate the transcription of a chimeric reporter plasmid utilizing the consensus promoter sequence of BAX approximately 50-fold over mutant p53. Thus it is likely that p53 promotes BAX's apoptotic faculties in vivo as a primary transcription factor. However, p53 also has a transcription-independent role in apoptosis. In particular, p53 interacts with BAX, promoting its activation as well as its insertion into the mitochondrial membrane.", "paragraph_text": "The expression of BAX is upregulated by the tumor suppressor protein p53, and BAX has been shown to be involved in p53-mediated apoptosis. The p53 protein is a transcription factor that, when activated as part of the cell's response to stress, regulates many downstream target genes, including BAX. Wild-type p53 has been demonstrated to upregulate the transcription of a chimeric reporter plasmid utilizing the consensus promoter sequence of BAX approximately 50-fold over mutant p53. Thus it is likely that p53 promotes BAX's apoptotic faculties in vivo as a primary transcription factor. However, p53 also has a transcription-independent role in apoptosis. In particular, p53 interacts with BAX, promoting its activation as well as its insertion into the mitochondrial membrane."}, {"title": "P53 p63 p73 family Evolution", "content": "P53, p63, and p73 have similar features in their gene structures and functions but have also diverged evolutionarily. The p53 family evolved from a p63/p73 ancestor gene in invertebrates. P53 diverged from p63/p73 with a gene duplication in the cartilaginous fish. P63 and p73 differentiated from each other in bony fish. These genes developed different functions and structures throughout their evolutionary divergence (TP73L, p73, p53)", "is_supporting": false, "idx": 94, "question_id": "case_study_biomed/question_14.json", "text": "P53, p63, and p73 have similar features in their gene structures and functions but have also diverged evolutionarily. The p53 family evolved from a p63/p73 ancestor gene in invertebrates. P53 diverged from p63/p73 with a gene duplication in the cartilaginous fish. P63 and p73 differentiated from each other in bony fish. These genes developed different functions and structures throughout their evolutionary divergence (TP73L, p73, p53)", "paragraph_text": "P53, p63, and p73 have similar features in their gene structures and functions but have also diverged evolutionarily. The p53 family evolved from a p63/p73 ancestor gene in invertebrates. P53 diverged from p63/p73 with a gene duplication in the cartilaginous fish. P63 and p73 differentiated from each other in bony fish. These genes developed different functions and structures throughout their evolutionary divergence (TP73L, p73, p53)"}, {"title": "Guillermina Lozano Career", "content": "Lozano is recognised for her studies of the p53 tumour suppressor pathway, from characterising p53 as a transcriptional activator to revealing the importance of two inhibitors of p53, Mdm2 and Mdm4.", "is_supporting": false, "idx": 95, "question_id": "case_study_biomed/question_14.json", "text": "Lozano is recognised for her studies of the p53 tumour suppressor pathway, from characterising p53 as a transcriptional activator to revealing the importance of two inhibitors of p53, Mdm2 and Mdm4.", "paragraph_text": "Lozano is recognised for her studies of the p53 tumour suppressor pathway, from characterising p53 as a transcriptional activator to revealing the importance of two inhibitors of p53, Mdm2 and Mdm4."}, {"title": "BUB1 Link to caspase-independent mitotic death (CIMD)", "content": "It has also been proposed that Bub1 binds p53 to prevent it from activating pro-apoptotic genes, therefore p53 is able to induce apoptosis when Bub1 is depleted. However, an interaction between p53 and Bub1 has not yet been shown while p53 binding BubR1 has been reported.", "is_supporting": false, "idx": 96, "question_id": "case_study_biomed/question_14.json", "text": "It has also been proposed that Bub1 binds p53 to prevent it from activating pro-apoptotic genes, therefore p53 is able to induce apoptosis when Bub1 is depleted. However, an interaction between p53 and Bub1 has not yet been shown while p53 binding BubR1 has been reported.", "paragraph_text": "It has also been proposed that Bub1 binds p53 to prevent it from activating pro-apoptotic genes, therefore p53 is able to induce apoptosis when Bub1 is depleted. However, an interaction between p53 and Bub1 has not yet been shown while p53 binding BubR1 has been reported."}, {"title": "Karen Vousden Research", "content": "p53 can also help to prevent or repair minor damage to the genome under conditions of low stress. Vousden's group have recently discovered a novel p53-regulated protein, TIGAR (T-p53 Inducible Glycolysis and Apoptosis Regulator), which can reduce oxidative stress in cells and might mediate part of this effect of p53.", "is_supporting": false, "idx": 97, "question_id": "case_study_biomed/question_14.json", "text": "p53 can also help to prevent or repair minor damage to the genome under conditions of low stress. Vousden's group have recently discovered a novel p53-regulated protein, TIGAR (T-p53 Inducible Glycolysis and Apoptosis Regulator), which can reduce oxidative stress in cells and might mediate part of this effect of p53.", "paragraph_text": "p53 can also help to prevent or repair minor damage to the genome under conditions of low stress. Vousden's group have recently discovered a novel p53-regulated protein, TIGAR (T-p53 Inducible Glycolysis and Apoptosis Regulator), which can reduce oxidative stress in cells and might mediate part of this effect of p53."}, {"title": "Oncovirus DNA Oncoviruses", "content": "Viruses employ various methods of inactivating p53. The adenovirus E1B protein (55K) prevents p53 from regulating genes by binding to the site on p53 which binds to the genome. In SV40, the large T antigen (LT) is an analogue; LT also binds to several other cellular proteins, such as p107 and p130, on the same residues. LT binds to p53\u2019s binding domain on the DNA (rather than on the protein), again preventing p53 from appropriately regulating genes. HPV instead degrades p53: the HPV protein E6 binds to a cellular protein called the E6-associated protein (E6-AP, also known as UBE3A), forming a complex which causes the rapid and specific ubiquitination of p53.", "is_supporting": false, "idx": 98, "question_id": "case_study_biomed/question_14.json", "text": "Viruses employ various methods of inactivating p53. The adenovirus E1B protein (55K) prevents p53 from regulating genes by binding to the site on p53 which binds to the genome. In SV40, the large T antigen (LT) is an analogue; LT also binds to several other cellular proteins, such as p107 and p130, on the same residues. LT binds to p53's binding domain on the DNA (rather than on the protein), again preventing p53 from appropriately regulating genes. HPV instead degrades p53: the HPV protein E6 binds to a cellular protein called the E6-associated protein (E6-AP, also known as UBE3A), forming a complex which causes the rapid and specific ubiquitination of p53.", "paragraph_text": "Viruses employ various methods of inactivating p53. The adenovirus E1B protein (55K) prevents p53 from regulating genes by binding to the site on p53 which binds to the genome. In SV40, the large T antigen (LT) is an analogue; LT also binds to several other cellular proteins, such as p107 and p130, on the same residues. LT binds to p53's binding domain on the DNA (rather than on the protein), again preventing p53 from appropriately regulating genes. HPV instead degrades p53: the HPV protein E6 binds to a cellular protein called the E6-associated protein (E6-AP, also known as UBE3A), forming a complex which causes the rapid and specific ubiquitination of p53."}, {"title": "P53", "content": "Tumor protein p53, also known as p53, cellular tumor antigen p53 (UniProt name), the Guardian of the Genome, phosphoprotein p53, tumor suppressor p53, antigen NY-CO-13, or transformation-related protein 53 (TRP53), is any isoform of a protein encoded by homologous genes in various organisms, such as TP53 (humans) and Trp53 (mice). This homolog (originally thought to be, and often spoken of as, a single protein) is crucial in multicellular vertebrates, where it prevents cancer formation, and thus functions as a tumor suppressor. As such, p53 has been described as \"the guardian of the genome\" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene.", "is_supporting": false, "idx": 99, "question_id": "case_study_biomed/question_14.json", "text": "Tumor protein p53, also known as p53, cellular tumor antigen p53 (UniProt name), the Guardian of the Genome, phosphoprotein p53, tumor suppressor p53, antigen NY-CO-13, or transformation-related protein 53 (TRP53), is any isoform of a protein encoded by homologous genes in various organisms, such as TP53 (humans) and Trp53 (mice). This homolog (originally thought to be, and often spoken of as, a single protein) is crucial in multicellular vertebrates, where it prevents cancer formation, and thus functions as a tumor suppressor. As such, p53 has been described as \"the guardian of the genome\" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene.", "paragraph_text": "Tumor protein p53, also known as p53, cellular tumor antigen p53 (UniProt name), the Guardian of the Genome, phosphoprotein p53, tumor suppressor p53, antigen NY-CO-13, or transformation-related protein 53 (TRP53), is any isoform of a protein encoded by homologous genes in various organisms, such as TP53 (humans) and Trp53 (mice). This homolog (originally thought to be, and often spoken of as, a single protein) is crucial in multicellular vertebrates, where it prevents cancer formation, and thus functions as a tumor suppressor. As such, p53 has been described as \"the guardian of the genome\" because of its role in conserving stability by preventing genome mutation. Hence TP53 is classified as a tumor suppressor gene."}, {"title": "P53 Experimental analysis of p53 mutations", "content": "Most p53 mutations are detected by DNA sequencing. However, it is known that single missense mutations can have a large spectrum from rather mild to very severe functional affects.", "is_supporting": false, "idx": 100, "question_id": "case_study_biomed/question_14.json", "text": "Most p53 mutations are detected by DNA sequencing. However, it is known that single missense mutations can have a large spectrum from rather mild to very severe functional affects.", "paragraph_text": "Most p53 mutations are detected by DNA sequencing. However, it is known that single missense mutations can have a large spectrum from rather mild to very severe functional affects."}]